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Dysfunction of the vascular 
endothelium can lead to diseases 
such as atherosclerosis. In this 
thesis, the signaling potential 
of endogenous lipid oxidation 
and nitration products in the 
endothelium was investigated. 
The results demonstrate that 
electrophilic lipid oxidation and 
nitration products participate to 
cytoprotection via Nrf2 and HSF1 
transcription factors and may 
protect against early events of 
vascular diseases. 
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ABSTRACT 
 
Electrophilic products of lipid oxidation and nitration such as oxidized 1-palmitoyl-2-
arachidonoyl-sn-glycero-3-phosphocholine (oxPAPC) and nitro-fatty acids are potent 
signaling molecules in the vascular system. Electrophiles not only contribute to disease 
pathology but can also function as mediators of cytoprotective responses. The Keap1-Nrf2-
ARE signaling pathway regulates a wide variety of antioxidant enzymes in response to 
oxidative stress or electrophilic stimuli. Upon activation, the inhibitor protein Keap1 is 
modified allowing the activation of transcription factor Nrf2 and the subsequent 
production of antioxidant enzymes. 
The aim of this thesis was to investigate the cytoprotective pathways activated by 
oxPAPC and nitro-oleic acid (OA-NO2), focusing on Nrf2 signaling. Both lipids were found 
to induce the expression of antioxidant enzymes in human primary endothelial cells, and 
oxPAPC also in murine arteries, in Nrf2-dependent manner. In addition, epoxyisoprostane 
and hydroperoxide phospholipids (PEIPC and PAPCOOH, respectively) were identified as 
the Nrf2 activating species in oxPAPC and furthermore, the electrophilic sn-2 side chain in 
the phospholipids appeared to be critical for activation of Nrf2 target genes.  
Genome-wide analysis of Nrf2-dependent and -independent effects of OA-NO2 on gene 
expression in human endothelial cells revealed that in addition to Nrf2, OA-NO2 also 
induced another signaling pathway, the heat shock response. These two pathways worked 
independently of each other and may both serve as mediators of the cytoprotective effects 
of OA-NO2 in the vasculature. Furthermore, OA-NO2 robustly upregulated the endothelin 
receptor B (ETB), a receptor involved in blood pressure control, via Nrf2. 
The molecular mechanism by which OA-NO2 activated Nrf2 involved a modification of 
Keap1 cysteines C38, C226, C273, C288, and C489. In contrast to several Nrf2 activators, 
Keap1 C151 was found not to be the sensor for OA-NO2 nor was it needed for the activation 
of Nrf2 in response to OA-NO2. The data suggests that OA-NO2 may share the activation 
mechanism with cyclopentanone prostaglandins using C273 or/and C288 in Keap1 as a 
sensor for Nrf2 activation.     
These results demonstrate that in addition to exerting potentially pathological effects, 
lipid oxidation and nitration products can be protective signaling mediators in the vascular 
system, and may confer protection against the early events leading to vascular diseases. 
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TIIVISTELMÄ  
 
Elektrofiilisten yhdisteiden on yleensä ajateltu olevan elimistölle haitallisia hapettavien 
ominaisuuksiensa vuoksi. Kohtuullisina pitoisuuksina ne pystyvät kuitenkin myös 
toimimaan viestinviejinä säätelemällä spesifisesti signaalireittejä. Elektrofiilisten 
yhdisteiden tiedetään mm. aktivoivan Nrf2-transkriptiotekijää, joka osallistuu 
solupuolustukseen säätelemällä useiden antioksidanttientsyymien ilmentymistä.  
Tämän väitöskirjatutkimuksen tavoitteena oli selvittää hapettuneiden fosfolipidien ja 
nitrattujen rasvahappojen aktivoimia, solupuolustukseen osallistuvia signaalireittejä 
keskittyen erityisesti Nrf2-transkriptiotekijään. Sekä hapettuneen 1-palmitiini-2-arakidoni-
sn-glysero-3-fosfokoliinin (oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-
phosphocholine, oxPAPC) että nitratun öljyhapon (nitro-oleic acid, OA-NO2) havaittiin 
lisäävän antioksidanttientsyymien ilmentymistä ihmisen verisuonen endoteelisoluissa 
Nrf2-välitteisesti. Sama havaittiin myös hiiren kaulavaltimossa oxPAPC:n vaikutuksesta. 
Elektrofiiliset epoksi-isoprostaani-fosfolipidi ja hydroperoksidi-fosfolipidi tunnistettiin 
Nrf2:ta aktivoiviksi oxPAPC:n hapettumistuotteiksi. Lisäksi havaittiin, että Nrf2-välitteisten 
antioksidanttientsyymien ilmentymisen lisääntymiseen tarvitaan hapettuneissa 
fosfolipideissä nimenomaan elektrofiilinen sn-2-sivuketju. 
Selvitettäessä OA-NO2:n vaikutuksia geenien ilmentymiseen koko genomin laajuisesti 
havaittiin OA-NO2:n aktivoivan Nrf2-välitteisen ilmentymisen lisäksi toista 
solupuolustukseen osallistuvaa signaalireittiä, lämpöshokkivastetta (heat shock response). 
Tulosten perusteella voidaan olettaa, että nämä kaksi toisistaan riippumatonta reittiä 
välittävät OA-NO2:n suojaavia vaikutuksia verisuonistossa. Lisäksi OA-NO2:n todettiin 
voimakkaasti ja Nrf2-välitteisesti lisäävän endoteliinireseptori B:n (endothelin receptor B, 
ETB) ilmentymistä endoteelisoluissa. ETB on reseptori, joka säätelee verenpainetta. 
Tutkimuksessa selvitettiin myös spesifinen mekanismi, jolla OA-NO2 aktivoi Nrf2-
välitteistä signalointia. OA-NO2:n huomattiin sitoutuvan Nrf2:n inhibiittorin, Keap1:n, 
kysteiineihin 28, 226, 273, 288 ja 498, joista kysteiinit 273 ja 288 todettiin myös 
funktionaalisesti välttämättömiksi Nrf2:n aktivoinnin kannalta. Lisäksi havaittiin, että 
toisin kuin useiden muiden elektrofiilien vaikutuksesta, OA-NO2-käsittelyssä Keap1:n 
kysteiini 151 ei osallistu Nrf2:n säätelyyn. Julkaistujen tulosten ja tässä väitöskirjassa 
esitettyjen havaintojen perusteella voidaan olettaa, että Nrf2-signaalireitillä OA-NO2:n 
havaitaan toimivan Keap1:n kysteiini 273- ja/tai 288 -välitteisesti.  
Tutkimuksen tulokset osoittavat, että elektrofiiliset nitratut rasvahapot ja hapettuneet 
fosfolipidit ovat viestinviejiä, jotka aktivoivat solupuolustukseen osallistuvia 
signaalireittejä ja suojaavat siten verisuonistoa vaurioilta. 
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 1 Introduction 
Electrophilic products of lipid oxidation and nitration are potent signaling mediators in the 
vascular system. Not only do they contribute to disease pathology but they can also 
function as mediators of cytoprotective responses (Rudolph & Freeman 2009). Oxidized 
phospholipids such as oxidized 1-palmitoyl-2-arachidonoyl-sn-3-glycero-phosphocholine 
(oxPAPC), present in minimally modified low density lipoprotein (mmLDL), play a role in 
the development of atherosclerosis. For example, oxPAPC upregulates the production of 
adhesion molecules, inflammatory cytokines and chemokines, and increases monocyte 
adhesion onto endothelial cells (Furnkranz et al., 2005; Subbanagounder et al., 2002). 
However, in addition to these well-characterized proinflammatory and proatherogenic 
effects, oxPAPC can induce the expression of certain anti-inflammatory and cytoprotective 
enzymes such as heme oxygenase-1 (HO-1) (Ishikawa et al., 1997; Kronke et al., 2003) and 
glutamate cysteine ligase (GCL) (Moellering et al., 2002). Both of these genes are under the 
regulation of a transcription factor called nuclear factor-E2-related factor 2 (Nrf2), which 
can also be activated by oxPAPC (Li et al., 2007).  
Nitration products of unsaturated fatty acids are formed in nitric oxide  
(·NO) -dependent oxidative reactions. Nitro-fatty acids are electrophiles that react with 
nucleophilic residues in proteins thereby altering specific signaling pathways (Freeman et 
al., 2008). Nitro-fatty acids have been shown to be protective in mouse models of vascular 
diseases. Conferring protection against myocardial ischemia/reperfusion (I/R) injury, 
inhibiting neointimal thickening after femoral artery injury, and reducing the lesion size 
and inflammatory gene expression in atherosclerotic apolipoprotein E knockout (apoE-/-) 
mice. These effects are thought to be mediated by a direct modification of the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) p65 subunit and the subsequent 
inhibition of inflammation (Cole et al., 2009; Rudolph et al., 2010a; Rudolph et al., 2010b). 
Furthermore, HO-1 as well as Nrf2 have been postulated to play a role in the protective 
effects of nitro-fatty acids (Cole et al., 2009; Villacorta et al., 2007).  
Nrf2 is a transcription factor that regulates a wide array of cytoprotective genes 
including HO-1, GCL and NAD(P)H quinone oxidoreductase-1 (NQO1). Nrf2 is tightly 
regulated by the inhibitor protein Kelch-like ECH-associated protein 1 (Keap1), which 
under basal conditions facilitates the rapid ubiquitination and degradation of Nrf2 (Itoh et 
al., 1999). In response to oxidative stress or the presence of electrophiles, specific cysteine 
residues in Keap1 are modified allowing Nrf2 to escape the degradation pathway, 
translocate to the nucleus where it binds to the antioxidant response element (ARE) in the 
target genes driving their expression (Dinkova-Kostova et al., 2002). 
Endogenous molecules oxPAPC and nitro-fatty acids are known to participate in 
cytoprotection in the vasculature, but the detailed molecular mechanisms are not 
understood. Nrf2 is recognized as being one of the major transcription factors regulating 
the expression of cytoprotective enzymes. Therefore, the aim of this thesis was to 
investigate the molecular mechanism by which oxPAPC and nitro-oleic acid (OA-NO2) 
participate in the cytoprotection of endothelial cells focusing on Nrf2 signaling. More 
specifically, the aim was to elucidate the Nrf2 activating capacity of oxPAPC in human 
endothelial cells and mouse carotid arteries and to characterize which lipid species are 
involved in evoking this effect. Furthermore, the Nrf2-dependent and -independent effects 
of OA-NO2 on gene expression in human endothelial cells using genome-wide 
transcriptional profiling were investigated. In addition, the molecular mechanism by which  
OA-NO2 activates transcription factor Nrf2 was investigated, focusing on the post-
translational modifications of cysteine residues in Keap1 via nitroalkylation and subsequent 
downstream effects. Finally, the effect of OA-NO2 on Nrf2-dependent induction of the 
endothelin receptor B (ETB) gene in endothelial cells was studied. 
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2 Review of the literature 
2.1 VASCULAR ENDOTHELIUM 
The vascular endothelium is the thin layer of cells that line blood vessels. It functions as a 
barrier between the vessel lumen and the surrounding tissue, controlling the passage of 
materials into and out of the bloodstream. In addition, blood vessels adapt to the 
surrounding environment by changing their shape and size in order to ensure a constant 
flow of blood. This adaptation is influenced by the endothelium through multiple 
mechanisms. The endothelium can produce growth promoting and inhibiting substances, 
and modulate thrombosis by the secretion of procoagulant, anticoagulant, and fibrinolytic 
agents. The endothelium can also influence inflammatory responses by expressing 
adhesion molecules that bind immune cells. Furthermore, the endothelium regulates 
vascular tone by secreting vasoactive substances that influence smooth muscle cell 
contraction. Dysfunction of the endothelium plays a critical role in the pathogenesis of 
many vascular diseases such as atherosclerosis (Chiu & Chien 2011). 
2.1.1 Development and organization of the vascular system 
The vascular system consists of three main types of blood vessels that carry blood 
throughout the body; arteries, veins and capillaries. The heart pumps oxygen rich blood 
through arteries to capillaries from which the oxygen and nutrients diffuse to tissues. The 
deoxygenated blood is carried from capillaries to veins and back to the heart. In addition, 
arteries control the local blood flow by contracting and dilating in order to supply the 
oxygen and nutrients required for tissue activity, and veins provide a reservoir function by 
storing large quantities of blood that can be sent to the arterial side if the blood pressure 
falls too low (Guyton & Hall 2000).  
New blood vessels can be formed via differentiation, migration and coalescence of 
endothelial progenitor cells (vasculogenesis), and by vascular growth of new capillaries 
from pre-existing vessels (angiogenesis). Vasculogenesis occurs mainly during embryonic 
development, when endothelial cells form a tree-like tubular network of blood vessels, 
which matures into a vasculature that consists of arteries, vein and capillaries. 
Angiogenesis is a crucial mechanism for tissue regeneration, such as wound healing, but it 
occurs also in pathological conditions such as tumor growth (Herbert & Stainier 2011).  
Blood vessels consist predominantly of endothelial cells, smooth muscle cells, and the 
extracellular matrix. Three concentric layers, intima, media and adventitia, are most clearly 
defined in larger vessels (Figure 1). In arteries, the intima consists of thin endothelial cell 
layer supported by a subendothelial layer of connective tissue, which contains occasional 
smooth muscle cells. The intima is separated from the media by an internal elastic lamina, 
which consisted mainly of elastin. Internal elastic lamina has gaps, called fenestrae, that 
permit the diffusion of compunds needed by the cells deeper in the arterial wall. The media 
layer consists mainly of smooth muscle cells that by contraction and relaxation, maintain an 
appropriate blood pressure. The external elastic lamina separates the media layer from the 
adventitia. The adventitia consists principally of collagen and elastic fibers and becomes 
continuous with the connective tissue of which the vessel runs. The outer portion in large 
and medium sized arteries is nourished by small arterioles arising from outside the vessel, 
called vasa vasorum (Figure 1) (Kumar, Cotran, & Robbins 2003). 
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Figure 1. The organization of a medium size artery. The artery consists of three layers, intima, 
media and adventitia. The layers are separated by internal elastic lamina and external lamina. 
The main cell types of the vessel wall are endothelial cells and smooth muscle cells. The 
adventitia consists of connective tissue and has small arterioles, vasa vasorum.  
2.1.2 Redox reactions in the vasculature 
Molecular oxygen is essential for all aerobic organisms, but the reactive byproducts of 
oxygen metabolism, reactive oxygen species (ROS), can damage all components of the cell 
i.e. proteins, DNA and lipids. This paradox has led to the development of a carefully 
controlled maintenance system to ensure cellular redox balance, and the use of ROS under 
physiological conditions as signaling molecules (Thannickal & Fanburg 2000).  
Oxidative stress is described as an imbalance between the production of ROS and the 
ability of antioxidant systems to detoxify these reactive intermediates. In addition to being 
byproducts of the mitochondrial respiratory chain, many enzymes including NAD(P)H 
oxidase (Nox), 5-lipo-oxygenase (5-LOX) and nitric oxide synthase (NOS) produce ROS. 
The increased production of ROS is involved in many diseases including neurodegerative 
diseases, diabetes and atherosclerosis (Stocker & Keaney, Jr. 2004). 
ROS include both free radicals and nonradical oxidants. Free radicals such as  superoxide 
(·O2-), hydroxyl radical (·OH), peroxyl radical, organic hydroperoxides, and nitric oxide 
(·NO) contain one or more unpaired electrons. The reactions of two radical species are often 
kinetically fast and lead to the creating of nonradical products. An example relevant to the 
vessel wall is the reaction between ·O2- and ·NO, which leads to the production of 
peroxynitrite (ONOO-), which impairs ·NO bioavailability. More commonly, free radicals 
react with nonradical molecules, generate a new radical, and potentially trigger a chain 
reaction. Lipid peroxidation is a good example of this kind of chain reaction (Figure 4). In 
addition to free radicals, ROS also include nonradical oxidants such as hydrogen peroxide, 
hypochlorous acid and ONOO- (Stocker & Keaney, Jr. 2004).  
Antioxidants are molecules that can neutralize ROS by accepting or donating an electron 
thereby maintaining the redox balance in the cell. Cellular antioxidants include low-
molecular-weight agents such as glutathione (GSH), ascorbic acid, and α-tocopherol, and 
enzymes such as superoxide dismutase, catalase, glutathione peroxidase (GPx), glutathione 
reductase, glutathione S-transferase (GST), thioredoxin, and HO-1 (Stocker & Keaney, Jr. 
2004). Many of the cellular antioxidant enzymes are under the regulation of transcription 
factor Nrf2, which is activated by oxidative stress (Baird & Dinkova-Kostova 2011). The 
detailed regulation of the Nrf2 pathway is presented in chapter 2.3.1. 
2.1.3 Endothelium-derived vasoactive substances  
The endothelium can regulate blood flow and blood pressure by producing substances that 
can either contract or relax vascular smooth muscle cells, the major cell type present in 
blood vessels. The most important endothelium-derived vasoactive substances are ·NO, 
endothelins (ETs) and prostacyclin. Both ·NO and prostacyclin evoke vasodilatation by 
Fibroblast
1.
2.
3.
Lumen
1. Intima
Endothelium
Internal elastic lamina
2. Media
Smooth muscle cell
External lamina
3. Adventitia
Connetive tissue
Vasa vasorum
5 
 
 
relaxing vascular smooth muscle cells whereas ETs can either constrict or dilate vessels 
depending on which ET receptor is activated. In addition to endothelium-derived 
substances, there are other important regulators of vascular tone. For example, Angiotensin 
II (AngII), which is part of the renin-angiotensin-aldosterone system, is a major 
vasoconstrictor (Flammer & Luscher 2010). 
2.1.3.1 Nitric oxide 
Initially it was found that endothelial cells were producing an unknown molecule that was 
able to relax vascular smooth muscle and in 1987 this molecule was identified as ·NO 
(Ignarro et al., 1987). ·NO is formed from the amino acid L-arginine by the family of NOSs. 
The NOS family consists of three isoforms, which are encoded by three distinct genes. 
Endothelial NOS (eNOS) was first isolated from endothelial cells, neuronal NOS (nNOS) 
from neural cells, and inducible NOS (iNOS) from macrophages. nNOS and eNOS are 
constitutively expressed, nNOS predominantly in the nervous system and eNOS in 
endothelial cells, and these two enzymes produce ·NO under basal conditions as well as 
after stimulation. The production of iNOS is strongly induced by various stimuli including 
microbiological toxins and proinflammatory cytokines. During inflammatory conditions, 
iNOS produces ·NO (Tsutsui et al., 2010). Originally it was thought that the expression 
patterns of NOS are cell specific, but now it is appreciated that for example in the vascular 
system, all three NOS isoforms can exert the same functions, i.e. either physiological or 
pathophysiological (Li & Forstermann 2000). 
In addition to being a major vasodilator, ·NO prevents platelet adhesion and 
aggregation, as well as leukocyte adhesion and migration into the arterial wall, and inhibits 
smooth muscle cell proliferation (Pacher, Beckman, & Liaudet 2007). Since these features 
are a characteristic of the development of atherosclerosis (Lusis 2000), it is clear that ·NO 
plays a crucial role in maintaining healthy homeostasis in the vasculature. Furthermore, 
·NO is a free radical that in pathological conditions, such as those associated with increased 
oxidative stress and inflammation, reacts with ·O2- and produces a highly reactive oxidant, 
ONOO-. ONOO- can evoke cell damage via lipid peroxidation, by inactivation of enzymes 
and other proteins by oxidation and nitration. The production of ONOO- also decreases 
·NO bioavailability thereby impairing both vascular relaxation as well as other key 
functions of ·NO  (Pacher, Beckman, & Liaudet 2007).  
2.1.3.2 Endothelins 
Human endothelin family contains three isopeptides, endothelin-1, endothelin-2, and 
endothelin-3 (ET-1, ET-2, and ET-3). Endothelial cells are the predominant source of ET-1, 
which is the major ET in the vascular system. Even though ET-1 was first identified as a 
powerful vasoconstrictor, it can also act as a vasodilator depending on which receptor it 
activates. Two receptor subtypes, ETA and ETB mediate the effects of ET-1. In the vascular 
system, the ETA receptor is found predominantly in smooth muscle cells whereas the ETB 
receptor in abundantly expressed in endothelial cells. However, a sub-family of ETB 
receptors is also found in vascular smooth muscle cells. Both ETA and ETB receptors located 
in smooth muscle cells promote vasoconstriction, but the activation of the ETB receptors 
located in endothelial cells evokes vasodilatation (Figure 2) (Schneider, Boesen, & Pollock 
2007). The exact way in which the ET system regulates vascular tone and blood pressure is 
not fully understood. The opposing roles of ETA and ETB receptors, irreversible nature of 
ligand binding to the ET receptors, the fact that plasma levels no not correlate with the 
synthesis of ET-1, and the lack of global ET and ET receptor knockout mouse models 
present a great challenges in this field of research (Pollock 2010). Nevertheless, it is thought 
that ETB stimulates endothelial cells to produce ·NO and other vasodilators that exert 
vasorelaxant effects on the underlying smooth muscle cells (Figure 2). Since ETA receptor 
blockade produces either a small decrease or no change in mean arterial pressure while ETB 
antagonism increases mean arterial pressure, it is possible that the ETB receptor might have 
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a more important role in regulating basal blood pressure and vascular tone (Schneider, 
Boesen, & Pollock 2007).    
In certain vascular diseases, such as atherosclerosis, vascular ET-1 production is 
elevated, especially in the aortic arches that are particularly prone to the development of 
atherosclerotic lesions. In addition, ET-1 accumulates in lesions, and the numbers of ET 
receptors increase. Furthermore, treatment with an ETA antagonist delays the development 
of atherosclerosis, but does not change blood pressure or cholesterol levels (Kedzierski & 
Yanagisawa 2001). 
 
 
Figure 2. Endothelin system. ETA receptor in smooth muscle cells mediates the constricting 
effect of ET-1. Stimulation of ETB receptor in endothelial cells by ET-1 increases the production 
of ·NO and lead to dilatation of smooth muscle cells.  
2.1.4 Shear stress 
The vascular endothelial cell monolayer is located in the interface between blood and the 
vessel wall. The endothelium is in direct contact with the pulsatile flow of blood, and 
exposed to the different hemodynamic forces generated in the branched organization of the 
blood vessels. Shear stress can be described as the force arising from blood flow and acting 
in parallel to the vessel surface. Blood flow patterns can naturally vary from relatively 
uniform laminar flow (high shear stress) in the unbranched medium-sized arteries to 
complex disturbed laminar flow (low shear stress) near to branch points, bifurcations, and 
major curves. In addition, disturbed flow patterns are common in many pathological 
conditions such as near to atherosclerotic plaques, as well as following some interventional 
procedures e.g. stent deployment in balloon angioplasty (Chiu & Chien 2011).  
Fluid shear stress can influence the structure and function of the endothelium and 
modulate the gene expression pattern. For example, low shear areas are especially prone to 
atherosclerosis whereas areas with high shear stress are relatively well protected 
(Gimbrone, Jr. et al., 2000). In addition, the transcriptional response of healthy endothelial 
cells predisposed to high shear stress differs dramatically from the response of endothelial 
cells in areas of turbulent flow or decreased shear stress. In decreased shear stress areas, the 
cells express increased levels of inflammatory genes that are under regulation of the 
transcription factor NF-κB. These include inter-cellular adhesion molecule-1 (ICAM-1), 
vascular cellular adhesion molecule-1 (VCAM-1), monocyte chemotactic protein-1 (MCP-1), 
and E-selectin (Takabe, Warabi, & Noguchi 2011). These genes are associated with 
endothelial dysfunction and with the development of atherosclerosis (Chiu & Chien 2011). 
In contrast, healthy endothelial cells in the areas of high or normal shear stress express anti-
inflammatory and anticoagulant genes (Gimbrone, Jr. et al., 2000). Among the protective 
genes, about 70% are under the regulation of two transcription factors, Nrf2 and Krüppel-
like factor 2 (KLF2) (Fledderus et al., 2008). Nrf2 regulates a wide variety of antioxidant and 
anti-inflammatory genes and KLF2 induces the synthesis of anti-inflammatory and 
anticoagulant proteins, such as eNOS and thrombomodulin (Boon & Horrevoets 2009). In 
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addition to Nrf2 and KLF2, heat shock response (HSR) might have a beneficial role in the 
protection against atherosclerosis. An affymetrix gene expression analysis of cultured 
endothelial cells has revealed that atheroprotective pulsatile laminar flow can induce the 
expression of HSPA1A, a gene that encodes heat shock 70kDa protein (HSP70), an 
important effector of HSR (Takabe, Warabi, & Noguchi 2011). 
2.1.5 Endothelial dysfunction 
A healthy endothelium is a major regulator of vascular homeostasis. It maintains vascular 
tone and structure by secreting vasoactive substances. In addition, the healthy endothelium 
regulates growth, thrombosis, and inflammatory responses. Endothelial dysfunction occurs 
when vascular homeostasis is disturbed leading to damage to the arterial wall. Multiple 
factors including disturbed laminar flow, increased oxidative stress, chronic hypertension, 
increased plasma concentration of oxidized low density lipoprotein (oxLDL) and its 
accumulation to the vessel well, and infection by bacteria, viruses and other pathogens are 
known to induce endothelial dysfunction (Chiu & Chien 2011).  
Most commonly, endothelial dysfunction is characterized by the loss of ·NO 
bioavailability. The loss of production or activity of ·NO is due to the decreased expression 
of the ·NO synthesizing enzyme NOS, or to increased oxidative stress. Oxidative stress 
increases the amount of ROS, including O2-, which can react with ·NO to form ONOO- and 
in this way to reduce ·NO bioavailability. Since ·NO is a critical regulator of vascular 
homeostasis, the loss of its bioavailability leads to an imbalance between vasoconstriction 
and vasodilatation, as well as inhibition and stimulation of cell proliferation and migration. 
In addition, endothelial permeability, platelet aggregation, leukocyte adhesion, and the 
generation of cytokines are increased (Chiu & Chien 2011). All these properties of 
dysfunctional endothelium are also features associated with atherosclerosis. For example, 
an increase in the permeability of the endothelial cell layer allows macromolecules such as 
low density lipoprotein (LDL) to gain easier access to the intimal layer, where it can be 
oxidized and taken up by macrophages to form atherosclerotic lesions (Ross 1999). 
Increased expression of cytokines and chemotactic molecules such as MCP-1 as well as 
adhesion molecules including ICAM-1 and VCAM-1 maintain the presence of inflammation 
in atherosclerosis and encourage the recruitment and accumulation of monocytes and 
macrophages to the intima. Furthermore, altered regulation of vascular cells including 
decreased endothelial cell generation as well as increased smooth muscle cell proliferation 
and migration are the key features in atherosclerosis (Chiu & Chien 2011; Davignon & Ganz 
2004; Lusis 2000). Based on the molecular mechanisms of endothelial dysfunction, and the 
fact that it is considered as the initial event in atherosclerosis, it is not surprising that there 
is a correlation between endothelial dysfunction and the presence of coronary risk factors in 
individuals without clinical evidence of coronary disease. These facts emphasize the 
importance of vascular health in the prevention of atherosclerosis  (Davignon & Ganz 2004).  
2.1.5.1 Atherosclerosis 
Atherosclerosis is a disease of large arteries and the primary cause of coronary disease, 
stroke, and peripheral vascular diseases. It is a chronic inflammatory disease that 
progresses over several decades. The initial events encountered in atherosclerosis include 
endothelial dysfunction and increased oxidative stress, which promote the accumulation of 
cholesterol, macrophages and smooth muscle cells in the arterial wall to form a plaque and 
narrow the vessel lumen, impeding blood flow. In the late stages of atherosclerosis, the 
plaque may rupture exposing deep arterial components to blood flow, which will trigger 
the formation of thrombi and compromise oxygen supply to target organs such as the heart 
and brain. The major risk factors of atherosclerosis include an elevated LDL concentration, 
a reduced high density lipoprotein (HDL) concentration, hypertension, smoking, diabetes, 
obesity, and lack of physical activity (Lusis 2000).  
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2.1.5.1.1 Early events in atherosclerosis 
In healthy humans, lipoproteins transport lipids around the body in blood. LDL has a 
hydrophobic core that consists of cholesterol esters and triglycerides. Phospholipids, 
unesterified cholesterol, and apolipoprotein B100 surround the lipid core and form a 
hydrophilic membrane-like layer enabling the LDL particle to circulate in the blood. While 
LDL has an essential physiological role as a carrier of cholesterol to peripheral tissues, 
increased LDL levels are clearly associated with an increased risk of atherosclerosis 
(Steinberg 2009). The LDL particles that transport cholesterol to target tissues have to pass 
through the subendothelial space, intima, in order to reach their targets. Even though liver 
functions as an organ to remove excess LDL from the bloodstream, elevated plasma LDL 
concentrations lead to the accumulation of LDL in the intima (Glass & Witztum 2001). In 
addition to an elevated LDL concentration in plasma, dysfunction of the endothelium 
promotes the accumulation of LDL in the intima as well as accelerating inflammation in the 
vessel wall.  
 
 
Figure 3. Early events in the formation of an atherosclerotic plaque. LDL particles are oxidized in 
the intima of arteries because of increased production of ROS. OxLDL promotes endothelial cells 
to express adhesion molecules that bind monocytes. Monocytes migrate into the intima and are 
transformed into macrophages. The increased cytokine production by macrophages, endothelial 
cells and smooth muscle cells sustains inflammation in the vessel wall. Macrophages take up 
oxLDL and turn into foam cells. HDL facilities the removal of cholesterol from foam cells in a 
process of reverse cholesterol transport. Accumulating foam cells form a fatty streak, a 
precursor of the more advanced atherosclerotic lesion. Modified from (Lusis 2000).   
 
Increased oxidative stress followed by oxidation of LDL particles by ROS in the intima is 
another important feature in the early events of atherosclerosis (Figure 3). Oxidation first 
targets the phospholipids present in the outer layer of the LDL particle, followed by the 
modification of other lipid classes, and this converts LDL first to mmLDL and further to 
oxLDL. The properties of the oxidized phospholipids that are thought to account for the 
biological activity of mmLDL (Watson et al., 1995) are described in chapter 2.2.5. Oxidative 
modifications of LDL stimulate endothelial cells to express adhesion molecules such as P-
selectin, E-selectin, ICAM-1, and VCAM-1 on their surfaces. Monocytes adhere to these 
molecules, migrate into the intima, and differentiate into macrophages. Macrophages take 
up modified, especially oxidized, LDL primarily via the class A macrophage scavenger 
receptor and scavenger receptor CD36 as well as scavenger receptor class B member 1.  
In fact, initially macrophages have a protective function by removing cytotoxic and 
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proinflammatory oxLDL from the intima and transferring cholesterol to HDL particles to be 
transported out of the intima. HDL functions in a process called reverse cholesterol 
transport and removes cholesterol from the foam cells, therefore having a critical 
antiatherogenic role in the vessel wall (Farmer & Liao 2011). However, when the amount of 
modified LDL particles exceeds the removal capacity of macrophages, lipids start to build 
up in the cytoplasm of these cells and the macrophages turn into foam cells. Furthermore, 
the presense of oxLDL increases cytokine production in both macrophages and endothelial 
cells, which further induces the adhesion of inflammatory cells to endothelium and sustains 
chronic inflammation in the vessel wall (Ross 1999).  
Foam cells have droplets of cholesterol esters and some triacylglycerols in their 
cytoplasm and the accumulation of foam cells forms fatty streaks (Figure 3). They are not 
considered clinically significant but are thought of as precursors for more complex lesions 
(Glass & Witztum 2001; Lusis 2000). Most commonly atherosclerotic lesions develop in 
areas of disturbed blood flow and low shear stress such as arterial branch points, 
bifurcations, and major curves (Gimbrone, Jr. et al., 2000).  
2.1.5.1.2 Late stages of atherosclerosis 
A key feature in the development of an advanced atherosclerotic lesion is the proliferation 
and migration of smooth muscle cells from the medial layer into the intima. The 
proliferation is induced by the production of cytokines and growth factors by macrophages 
as well as by damage to the endothelial cell layer. Smooth muscle cells, together with the 
extracellular matrix that these cells produce, form a fibrous cap that covers the lipid core of 
the plaque. In the late stages of atherosclerosis, the plaque grows rapidly because of 
repetitive damage to the endothelium covering the plaque, followed by the thickening of 
the vessel wall. In the case of vulnerable plaques that have a thin fibrous cap, the rupture 
may be deep and the developing thrombi can block the artery. Advanced atherosclerotic 
lesions can lead to ischemic symptoms because of narrowing of the vessel lumen, but acute 
cardiovascular events such as myocardial infarction and stroke are thought to be a result 
from plaque rupture and thrombosis (Figure 4) (Glass & Witztum 2001; Lusis 2000).  
 
 
Figure 4. Lesion progression, plaque rupture, and thrombosis. Death of the foam cells leaves 
behind a growing mass of extracellular lipids. Cytokines and growth factors produced by 
macrophages induce the migration of smooth muscle cells from the medial layer to the intima. 
Vascular smooth muscle cells and the degraded matrix from a fibrous cap that covers the 
necrotic core of the lesion. Vulnerable plaques have thin fibrous caps that rupture easily. 
Rupture of the cap destroys the endothelial layer and exposes the lesion to blood components. 
The formation of a thrombus may be responsible for acute cardiovascular complications such as 
myocardial infarction or stroke. Modified from (Lusis 2000). 
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2.2 OXIDATION AND NITRATION PRODUCTS AS SIGNALING 
MEDIATORS 
2.2.1 Overview of lipid peroxidation 
Many of the endogenous electrophilic signaling mediators are products of lipid 
peroxidation. Similar to the elevated amounts of ROS during oxidative stress, the 
accumulation of electrophilic products can cause major tissue damage and cellular 
dysfunction in oxidative stress-related diseases such as neurodegerative diseases, diabetes 
and atherosclerosis. However, similar to the situation with ROS, moderate concentrations 
of lipid peroxidation products act as cellular regulators and signaling messengers (Rudolph 
& Freeman 2009). 
Lipid peroxidation most often affects the polyunsaturated fatty acids present in 
cholesterol esters, phospholipids, and triglycerides. Polyunsaturated fatty acids are fatty 
acids that contain more than one double bond in their backbone. They are prone to 
oxidation due to the presence of methylene groups, which are susceptible to hydrogen 
abstraction by free radicals, located between the double bonds. Lipid peroxidation proceeds 
by both non-enzymatic and enzymatic oxidation. Non-enzymatic, free radical-mediated 
lipid peroxidation is a chain reaction initiated by hydrogen abstraction by free radicals, for 
example ·OH, followed by a propagation step that generates a lipid peroxyl radical. The 
peroxyl radical can reduce itself to a lipid hydroperoxide by abstracting hydrogen from an 
adjacent polyunsaturated fatty acid generating additional radical species (Figure 5). In this 
way, one initiating free radical can oxidize many lipid molecules. Lipid hydroperoxides are 
the major primary products of free radical mediated lipid peroxidation of polyunsaturated 
fatty acids. In addition, singlet oxygen and ozone oxidize lipids through non-radical 
mechanisms. Moreover, enzymes such as LOXs, cyclo-oxygenases (COXs) and cytochrome 
P450 are the three enzymes predominantly responsible for the enzymatic oxidations of 
lipids (Niki 2009; West & Marnett 2006). 
 
Figure 5. Schematic overview of free radical mediated lipid peroxidation. 
2.2.2 Short chain aldehydes 
In the lipid peroxidation reactions, multiple short chain aldehydes such as acrolein, 
malondialdehyde, 4-hydroxy-2-nonenal (4-HNE), and 4-oxo-2-nonenal are formed (West & 
Marnett 2006). In fact, acrolein and 4-HNE protein adducts are often used as biomarkers for 
lipid peroxidation in vivo measured by antibodies directed against these markers  (Poli, 
Biasi, & Leonarduzzi 2008). 4-HNE has been the most extensively studied of the short chain 
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aldehydes. It has multiple cell signaling properties including activation of stress-related 
pathways such as the Nrf2 pathway and HSR (Jacobs & Marnett 2007).  
2.2.3 15-deoxy-Δ-12,14-prostaglandin J2 
Enzymatic lipid peroxidation of arachidonic acid by COX leads to the production of several 
prostaglandins. Prostaglandin D2 (PGD2) is a major COX product in many tissues and a 
precursor for the J series of cyclopentenone prostaglandins such as 15-deoxy-Δ-12,14-
prostaglandin J2 (15d-PGJ2). 15d-PGJ2 is an endogenous ligand for peroxisome proliferator-
activated receptor γ (PPAR-γ), a nuclear receptor that regulates adipocyte differentiation 
and metabolic homeostasis. In addition, 15d-PGJ2 mediates cytoprotection via activation of 
Nrf2-dependent detoxifying enzymes (Kansanen, Kivela, & Levonen 2009).  
2.2.4 Electrophilic oxo-derivates 
Recently a new class of electrophilic oxo-derivates (EFOX) was identified from activated 
macrophages. EFOXs are produced from omega-3 fatty acids in reactions mediated by the 
COX-2 enzyme. They are electrophiles that can inhibit the production of cytokines and 
activate the cytoprotective transcription factor, Nrf2 (Groeger et al., 2010).  
2.2.5 Oxidized phospholipids 
2.2.5.1 Structure and formation of oxidized phospholipids 
Unsaturated fatty acids present in biological molecules including phospholipids are also 
targets for lipid peroxidation. There are two major classes of phospholipids, one with a 
glycerol backbone (glycerophospholipids) and the other with a sphingosine group 
(sphingolipids). Glycerophospholipids consist of a glycerol backbone, a phosphate-
containing polar head group, and two fatty acid residues (sn-1 and sn-2 chains). Depending 
on the polar head group, glycerophospholipids are classified as 
glycerophosphatidylcholines (PC), glycerophosphatidylethanolamines (PE), 
glycerophosphatidylserines (PS), and glycerophosphatidylinositols (PI). Because of their 
amphipathic character, phospholipids form lipid bilayers. They organize with different 
types of molecules including proteins, cholesterol and glycolipids to form bilayers in cell 
structures such as cell membranes. The unsaturated fatty acids present in phospholipids 
can be oxidized by lipid peroxidation to generate products some of which are biologically 
active. The polyunsaturated fatty acid chains in phospholipids are targets for both non-
enzymatic and enzymatic oxidation. The non-enzymatic oxidation of polyunsaturated fatty 
acids present in phospholipids proceeds according to the same basic mechanism as lipid 
peroxidation of free polyunsaturated fatty acids described earlier (Figure 5). In contrast, the 
enzymatic oxidation significantly differs from the classical oxidation of free fatty acids. Of 
the known oxygenases, only 12/15-LOX is capable of oxidizing polyunsaturated fatty acids 
in phospholipids (Bochkov et al., 2010). 
PAPC is present in cell membranes and mmLDL. Due to the surface location and 
presence of polyunsaturated fatty acid chain, PAPC is prone to oxidation. Oxidation of the 
sn-2 fatty acid, arachidonic acid, in PAPC generates a variety of products including the 
species presented in Figure 6. It is known that the major structural determinant of oxPAPC 
lies in the sn-2 position, because the substitution of stearoyl for palmitoyl at the sn-1 
position or ethanolamine for choline at the sn-3 position of the phospholipid does not alter 
bioactivity as measured by inhibition of lipopolysaccaride (LPS) induced E-selectin 
expression (Subbanagounder et al., 2000). The oxidation products of PAPC can be separated 
into fragmented and non-fragmented oxidation products. The fragmented forms include 
structures generated by oxidative fragmentation of sn-2 fatty acid, such as 1-palmitoyl-2-(5-
oxovaleroyl)-sn-glycero-3-phosphocholine (POVPC) and 1-palmitoyl-2-glutaroyl-sn-
glycero-3-phosphocholine (PGPC). Non-fragmented lipids are generated by addition of 
oxygen atoms to the sn-2 fatty acid resulting in the formation of many species including 
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epoxyisoprostane (1-palmitoyl-2-5,6-epoxy isoprostane E2-sn-glycero-3-phosphocholine, 
PEIPC) or epoxycyclopentenone phospholipids (Subbanagounder, Watson, & Berliner 2000; 
Watson et al., 1999).  
 
 
Figure 6. Structures of 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (PAPC) and 
selected oxidized forms; POVPC, PGPC and PEIPC. 
2.2.5.2 Oxidized phospholipids in vascular inflammation and atherosclerosis 
Oxidation products of PAPC play a role in inflammation related vascular diseases such as 
atherosclerosis. For example, the biological activity of mmLDL results primarily from the 
oxidation of phospholipids such as PAPC (Watson et al., 1995). In addition, the analysis of 
atherosclerotic lesions has revealed the presence of multiple fragmented and oxygenated 
products of PAPC from cholesterol-fed rabbits (Watson et al., 1997), and there are natural 
antibodies to these oxidized phospholipids found in the sera of apoE-/- mice (Horkko et al., 
1996). Furthermore, oxPAPC induces monocyte binding to the endothelial cell layer 
(Leitinger et al., 1999; Watson et al., 1997) and the expression of several adhesion molecules 
and cytokines such as MCP-1, chemokine (C-X-C motif) ligand 1, chemokine (C-C motif) 
ligand 3 and 4 (Furnkranz et al., 2005; Subbanagounder et al., 2002). 
sn-1 fatty acid, 
palmitic acid
sn-2 fatty acid, 
arachidonic acid (AA)
Phosphatidylcholine (PC)
PAPC (1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine)
POVPC (1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-phosphocholine)
PGPC (1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphocholine)
PEIPC (1-palmitoyl-2-5,6-epoxy isoprostane E2-sn-glycero-3-phosphocholine)
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In addition to pro-inflammatory properties, oxidized phospholipids can act as anti-
inflammatory mediators in the vasculature. For example, oxPAPC has blocked the acute 
inflammatory reactions induced by LPS (Bochkov et al., 2002; Leitinger et al., 1999). In LPS-
injected mice, oxPAPC inhibited inflammation and protected mice from lethal endotoxin 
shock (Bochkov et al., 2002). In these mice as well as in vitro in endothelial cells, oxPAPC 
reduced the LPS-induced upregulation of inflammatory adhesion molecules including  
E-selectin and VCAM-1 as well as LPS-induced activation of inflammatory mediator  
NF-κB. Since NF-κB regulates the expression of these adhesion molecules, it was postulated 
that the inhibition of this signaling pathway was involved in the protection. Furthermore, 
POVPC was identified as one of the chemical structures in oxPAPC mediating these effects 
(Leitinger et al., 1999). It has been suggested that oxPAPC can block the effects of LPS by 
inhibiting LPS to act through its receptors, toll-like receptors 2 and 4 (Walton et al., 2003). 
oxPAPC also induces the expression of anti-inflammatory enzyme HO-1 (Ishikawa et al., 
1997; Kronke et al., 2003; Kronke et al., 2007). In addition, in endothelial cells, oxPAPC 
increases the amount of GSH, a major cellular antioxidant (Moellering et al., 2002), as well 
as the expression of GCL, a gene that encodes the rate limiting enzyme in the synthesis of 
GSH (Gargalovic et al., 2006b). Furthermore, oxPAPC can trigger the nuclear translocation 
of the antioxidant transcription factor Nrf2 and the expression of Nrf2 target gene oxidative 
stress-induced growth inhibitor (Li et al., 2007).  
2.2.6 Nitro-fatty acids 
2.2.6.1 Structure and formation of nitro-fatty acids 
In addition to being targets for direct lipid peroxidation, unsaturated fatty acids can react 
with ·NO and ·NO-derived species, such as ONOO-, yielding a variety of oxidized and 
nitrated derivates such as nitrated oleic (OA-NO2), linoleic (LNO2), linolenic, arachinonic 
and eicosapentaenoic acids (Lima, Di, & Abdalla 2003; Rubbo et al., 1994). The structures of 
the four isomers of LNO2, 9-nitro-9,12-octadecadienoic acid, 10-nitro-9,12-octadecadienoic 
acid, 12-nitro-9,12-octadecadienoic acid, and 13-nitro-9,12-octadecadienoic acids along with 
the two isomers of OA-NO2, 9-nitro-9-octadecenoic and 10-nitro-9-octadecenoic, are 
presented in Figure 7. LNO2 originates from linoleic acid, an omega-6 fatty acid abundant 
in many vegetable oils. OA-NO2 is a product of oleic acid (OA), omega-9 unsaturated fatty 
acid is present in various animal and vegetable fats, especially in olive oil. The nitro-fatty 
acids formed in these reactions are electrophilic and can react reversibly with the 
nucleophilic amino acids in proteins. The rate constant for these molecular species is  
2 orders of magnitude greater than for the electrophiles 4-HNE and 15d-PGJ2 (Baker et al., 
2007; Batthyany et al., 2006). 
Nitro-fatty acids OA-NO2 and LNO2 have been detected in vivo at low nM concentrations 
from plasma and tissue, and the concentrations are significantly elevated in inflammatory 
conditions such as ischemic preconditioning (IPC) and myocardial I/R (Nadtochiy et al., 
2009; Rudolph et al., 2010b; Tsikas et al., 2009). In the ex vivo IPC-model of the rat heart,  a 
concentration as high as 619±137 fmol/mg of mitochondrial protein was detected in 
mitochondria, which translates to an intramitochondrial concentration of 950 nM 
(Nadtochiy et al., 2009).  Analysis of mouse myocardial tissue after 30 min ischemia and  
30 min reperfusion revealed a 9.5±4.7 nM OA-NO2 concentration (Rudolph et al., 2010b).  
In vivo, nitro-fatty acids are rapidly metabolized to their saturated forms as well as being 
adducted to proteins. It has been demonstrated that after in vivo administration, a 
significant portion of OA-NO2 (18:1-NO2) is reduced to its unsaturated form, non-reactive 
18:0-NO2, and a moderate portion is saturated to 18:2-NO2. In addition, shorter fatty acid 
chain possessing, β-oxidation products of 18:1-NO2, 18:0-NO2 and 18:2-NO2 are formed. 
Importantly, the majority of 18:1-NO2 in the circulation is not present in the free form but is 
adducted to plasma proteins (Rudolph et al., 2009).  
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Figure 7. Structures of the four isomers of LNO2 (9-nitro-9,12-octadecadienoic acid, 10-nitro-
9,12-octadecadienoic acid, 12-nitro-9,12-octadecadienoic acid, and 13-nitro-9,12-
octadecadienoic acid) and the two isomers of OA-NO2 (9-nitro-9-octadecenoic and 10-nitro-9-
octadecenoic)  
2.2.6.2 Direct molecular targets of nitro-fatty acids 
Nitro-fatty acids can modulate specific signaling cascades by electrophilic adduction of 
biological targets. These compounds can alter the functions of regulatory proteins and 
enzymes via post-translational modification of the susceptible nucleophilic amino acids 
(Baker et al., 2007; Batthyany et al., 2006). The direct molecular targets of nitro-fatty acids 
include PPAR-γ (Schopfer et al., 2010), p65 subunit of NF-κB (Cui et al., 2006), 
glyceraldehyde 3-phosphate dehydrogenase (Batthyany et al., 2006), GSH (Baker et al., 
2007; Batthyany et al., 2006), xanthine oxidoreductase (Kelley et al., 2008), and matrix 
metalloproteinases (MMP) proMMP-7 and proMMP-9 (Bonacci et al., 2011).  
The first identified direct target of nitro-fatty acids was PPAR-γ, a nuclear receptor that 
regulates adipocyte differentiation and metabolic homeostasis. PPAR-γ is expressed in 
various cell types, including monocytes, macrophages, endothelial cells, vascular smooth 
muscle cells, and adipocytes (Baker et al., 2005; Freeman et al., 2008; Schopfer et al., 2005). 
In subsequent studies, cysteine (C) 285 of PPAR-γ was identified as the target cysteine  
to which OA-NO2 covalently binds (Schopfer et al., 2010). Synthetic PPAR-γ ligands, 
thiazolidinediones (TZDs), are used in the treatment of type 2 diabetes. They are beneficial 
in improving insulin sensitivity and lowering plasma glucose levels, but also have side 
effects, such as weight gain, fluid retention and hepatotoxicity (McGuire & Inzucchi 2008). 
Compared to TZDs, OA-NO2 induces more modest receptor activation, and undergoues 
unique coregulator interactions leading to a restoration of insulin sensitivity in vivo without 
inducing weight gain (Schopfer et al., 2010). 
The anti-inflammatory properties of nitro-fatty acids are mediated via a direct 
modification of the p65 subunit of NF-κB (Cui et al., 2006). NF-κB is a transcription factor 
that regulates a large number of genes that encode proinflammatory cytokines such as 
interleukin 6, MCP-1, VCAM-1, and tumor necrosis factor-α. The most predominant form 
of NF-κB is the heterodimer created from p50 and p65 subunits (Li & Verma 2002). The 
alkylation of the C38 in the p65 subunit is known to inhibit the DNA binding capacity of 
p65 and therefore to inhibit the proinflammatory cytokine production induced by NF-κB 
(Li & Verma 2002). Nitro-fatty acids can modulate the NF-κB response by inhibiting LPS- or 
I/R-injury-induced proinflammatory cytokine production both in vitro and in vivo (Cui et 
al., 2006; Rudolph et al., 2010b).  
In addition to modulation of NF-κB signaling, nitro-fatty acids may mediate protective 
responses through the activation of transcription factor Nrf2 (Villacorta et al., 2007). 
Furthermore, the expression of HO-1 is upregulated by nitro-fatty acids. In fact, HO-1 is 
9-nitro-9,12-octadecadienoic acid
10-nitro-9,12-octadecadienoic acid
12-nitro-9,12-octadecadienoic acid
13-nitro-9,12-octadecadienoic acid
9-nitro-9-octadecenoic acid
10-nitro-9-octadecenoic acid
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regulated by multiple transcription factors, one of which is Nrf2. HO-1 is upregulated by 
nitro-fatty acids in multiple cell types in vitro including human aortic endothelial cells 
(HAECs) (Wright et al., 2006), vascular smooth muscle cells (Khoo et al., 2010), rat aortic 
smooth muscle cells  (Cole et al., 2009), and mouse macrophages (Cui et al., 2006). The 
specific activation mechanism has not been studied in all cases, but LNO2 was able to 
induce HO-1 expression in HAECs independent of Nrf2 (Wright et al., 2009). 
2.2.6.3 Protective effects of nitro-fatty acids in in vivo models of vascular diseases 
Nitro-fatty acids have protective effects in various mouse models of vascular diseases. In a 
mouse model of myocardial I/R, the administration of OA-NO2 conferred protection against 
I/R injury. OA-NO2 reduced the infarct size 46% and preserved left ventricular function 
compared to vehicle treated mice. OA-NO2 treated animals had reduced myocardial p65 
levels, as well as lowered expression of two NF-κB regulated genes, ICAM-1 and MCP-1. In 
addition, using a mass spectrometry (MS) based β-mercaptoethanol (β-ME) exchange 
method, OA-NO2 adduction to NF-κB subunit p65 was assayed in heart tissue of OA-NO2 
treated mice whereas this was not detected in the vehicle group. These data indicate that 
the protective effect of OA-NO2 in myocardial I/R injury is at least in part mediated by the 
inhibition of the NF-κB pathway (Rudolph et al., 2010b). However, the results do not 
exclude involvement of additional protective pathways. In addition to the myocardial I/R 
model, a kidney I/R injury model has been used to study the in vivo effects of nitro-fatty 
acids. In this model, the administration of OA-NO2 was able to attenuate the renal I/R 
injury. As in the myocardial model, a reduction of the expression of proinflammatory 
cytokines was detected (Liu et al., 2008).  
In a mouse model where an endoluminal injury to the femoral artery was induced by an 
angioplasty wire, the administration of OA-NO2 significantly inhibited neointimal 
hyperplasia as measured by the intima/media ratio, and intimal area. The inhibition of 
neointimal formation was partly reversed when the injury was induced in HO-1 knockout 
mice. These results indicate that HO-1 is involved in reduced neointimal thickening (Cole et 
al., 2009), but suggest that  additional protective pathways may play a role. 
Apoe-/- mice fed with high fat diet for 12 weeks were used to investigate the effect of 
nitro-fatty acids on atherosclerosis. The administration of OA-NO2 reduced the lesion size 
as assessed from aortic sections and whole aortas by 32% and 29%, respectively. The  
OA-NO2 treatment was shown to reduce the levels of inflammatory cells in lesions as well 
as the expression of inflammatory cytokines including MCP-1, VCAM-1 and ICAM-1 
(Rudolph et al., 2010a). Even though the levels of proinflammatory cytokines that can be 
regulated by NF-κB were measured, the direct link to NF-κB, or to other pathways remains 
to be clarified.  
The role of OA-NO2 in hypertension has been studied in a mouse model where 
hypertension is induced by AngII infusion. The authors demonstrated that the systemic 
administration of OA-NO2 resulted in a sustained reduction of AngII-induced 
hypertension. The mechanism appeared to be independent of PPAR-γ and involved a 
covalent modification of the Angiotensin II type receptor (AT1R). However, OA-NO2 did 
not interfere with the binding of AngII and its receptor, AT1R, and thus the detailed 
activation mechanism remains to be determined  (Zhang et al., 2010).  
Since there are ligands for PPAR-γ, nitro-fatty acids are potential therapeutic agents for 
type 2 diabetes (Baker et al., 2005; Schopfer et al., 2010; Schopfer et al., 2005). In fact, the 
administration of OA-NO2 to ob/ob mice resulted in a reduction of glucose and insulin 
levels, comparable to TZD rosiglitazone, without the weight gain typical for treatment with 
the TZDs (Schopfer et al., 2010). 
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2.3 PROTECTIVE PATHWAYS ACTIVATED BY OXIDIZED AND NITRATED 
LIPIDS 
2.3.1 Keap1-Nrf2-ARE-pathway 
The Keap1-Nrf2-ARE-pathway is activated by oxidative stress and electrophilic compounds 
and has three major players all having essential roles in its activation and regulation. Keap1 
is the redox sensitive protein that in the presense of an oxidative or electrophilic stimulus, 
allows the activation of the transcription factor, Nrf2. Once activated, Nrf2 is translocated to 
the nucleus, binds to the AREs of the target genes, and drives their expression. The target 
genes of Nrf2 include multiple cytoprotective and antioxidant genes (Baird & Dinkova-
Kostova 2011; Itoh, Mimura, & Yamamoto 2010). 
Keap1 consists of five domains, the N-terminal domain, Broad complex, Tramtrack and 
Bric-à-Brac (BTB) domain, the intervening region (IVR), the Kelch domain, also known as 
double glycine repeats, and C-terminal domain (Figure 8). Keap1 is a homodimer that 
dimerizes through the BTB domain and forms a structure that resembles a “cherry-bob” 
(Ogura et al., 2010) (Figure 9B). In the cell, Keap1 is tethered to the cytoskeletal actin 
through the Kelch domain, which is also responsible for the Nrf2 binding of Keap1 (Itoh et 
al., 1999).  
Nrf2 consists of six Neh (Nrf2-ECH homology) domains (Neh1 - Neh6) (Figure 8). Neh1 
contains CNC basic region for DNA binding and a leucine zipper structure for dimerization 
with small Maf proteins (Itoh et al., 1997).  Neh3 (Nioi et al., 2005), Neh4 (Itoh et al., 1997) 
and Neh5 (Zhang et al., 2007) are transactivation domains. Neh2 is the domain that 
negatively regulates the transcriptional activity of Nrf2 via binding to the inhibitor protein 
Keap1 (Itoh et al., 1999) (Figure 8). 
ARE the sequence in the regulatory regions of cytoprotective genes where Nrf2 binds to. 
ARE was initially characterized to have a consensus core sequence TGACnnnGC 
(Rushmore, Morton, & Pickett 1991), which was further characterized and extended to 
TMAnnRTGAYnnnGCRwwww (Wasserman & Fahl 1997). Nrf2 preferably binds ARE 
with small Maf proteins, but other transcription factors such as as Nrf1, Nrf3, BTB and CNC 
homology (Bach) 1 and 2 have also been implicated in the regulation of ARE-dependent 
gene expression (Baird & Dinkova-Kostova 2011; Itoh, Mimura, & Yamamoto 2010). 
ARE activating agents were originally screened based on their ability to activate the ARE 
reporter construct and increase NQO1 activity (Prestera et al., 1993). These finding and 
subsequent studies (Itoh, Mimura, & Yamamoto 2010), revealed that ARE inducers belong 
to 10 different chemical classes. The only common feature of these diverse chemical 
compounds was that they could react with sulfhydryls such as cysteine thiols (Itoh, 
Mimura, & Yamamoto 2010). The discovery of the cysteine rich Keap1 in 1999 (Itoh et al., 
1999) and the finding that ARE activating chemicals bind Keap1 (Dinkova-Kostova et al., 
2002) confirmed the role of Keap1 as a sensor for ARE activating chemicals.  
 
 
 
Figure 8. Domain structures of Keap1 and Nrf2. Keap1 has the following domains: N-terminal 
domain, BTB-domain, IVR, Kelch domain and C-terminal domain. Nrf2 consists of six Neh 
domains. Modified from (Kansanen, Jyrkkanen, & Levonen 2011) 
Cul3 binding                   Nrf2
dimerization binding
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N-term C-termIVRBTB Kelch
Keap1 Nrf2
7K ETGEDLG
Keap1 binding     Transactivation Small Maf binding
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2.3.1.1 Keap1 as a sensor for electrophiles 
Keap1 responds to various stimuli including electrophiles, ROS and heavy metals leading 
to nuclear accumulation of Nrf2 and the subsequent activation of cytoprotective enzymes. 
Keap1 is an excellent example of a specific protein target of electrophiles in which covalent 
adduction leads to a specific biological effect, i.e. nuclear translocation of Nrf2, and thus to 
the activation of ARE-regulated genes. Keap1 sensor protein contains 27 cysteine residues 
and the key question is which of the cysteines in Keap1 are critical to its sensor function. 
Several in vitro analyses have identified multiple Keap1 cysteine residues as being be 
involved in the reaction with electrophiles.  
The most frequently reported targets, identified by MS methods, include C151, C257, 
C273, C288, C297, and C613 (Dinkova-Kostova et al., 2002; Eggler et al., 2005; Hong et al., 
2005; Hong, Freeman, & Liebler 2005; Hu et al., 2011; Kobayashi et al., 2009; Luo et al., 
2007). However, there are notable differences between laboratories studying mouse vs. 
human Keap1, different electrophilic probes, reaction concentrations, sample workups, and 
MS analysis methods. In addition to MS experiments, affinity purification using 
biotinylated electrophilic compounds and the avidin/streptavidin pull-down approach 
have been used to investigate the adduction of Keap1 by electrophiles (Hosoya et al., 2005; 
Levonen et al., 2004; Oh et al., 2008). These experiments have shown that cysteines in the 
IVR are critical for binding of electrophiles to Keap1, because the deletion of IVR but not 
the BTB domain or the Kelch domain abolishes binding (Hosoya et al., 2005).  
In addition to proteomic analyses of Keap1 cysteine modifications, the functional 
importance of individual Keap1 cysteines has been extensively investigated. The current 
data suggests that three cysteine residues C151, C273 and C288 are functionally the most 
important Keap1 cysteine residues. The IVR cysteines C273 and C288 are important for the 
ability of Keap1 to repress Nrf2 under basal conditions. The mutation of these cysteine 
residues results in the inability of Keap1 to inhibit ARE activation both under basal and 
electrophile induced conditions as assessed by reporter assays (Kobayashi et al., 2006; 
Levonen et al., 2004; Wakabayashi et al., 2004; Zhang & Hannink 2003). In addition, the lack 
of C273 in Keap1 diminished the levels of both cystoplasmic and nuclear Nrf2 protein as 
well as the ubiquitination of Nrf2 (Zhang et al., 2004). The ability of C273 and C288 to 
repress Nrf2 was further confirmed in vivo with a transgenic complementation rescue 
model. This study revealed that a single mutation of  could C273 or C288 inhibit the ability 
of Keap1 to repress Nrf2 in vivo under unstressed conditions resulting in the accumulation 
of Nrf2 protein and elevated levels of Nrf2 target genes (Yamamoto et al., 2008) confirming 
the in vitro findings. 
In addition to IVR cysteines C273 and C288, Keap1 BTB cysteine C151 has also an 
important, but very different role in the Keap1-Nrf2-ARE system. While C273 and C288 are 
critical for Keap1 to inhibit Nrf2 under basal conditions, C151 is important after induction 
of certain electrophiles. Sulforaphane (SFN) (Kobayashi et al., 2009; McMahon et al., 2010; 
Zhang & Hannink 2003), tert-butylhydroquinone (tBHQ) (Yamamoto et al., 2008; Zhang & 
Hannink 2003), N-iodoacetyl-N-biotinylhexylenediamine (IAB) (Rachakonda et al., 2008), 
diethyl maleate (DEM), ebselen (Kobayashi et al., 2009), and a tryptophan substitution of 
C151 (Eggler et al., 2009) activate Nrf2 and subsequent ARE-dependent gene expression in 
a Keap1 C151-dependent manner. These data are based on luciferase reporter assays 
(Eggler et al., 2009; Zhang & Hannink 2003), zebrafish embyos overexpressing mouse 
Keap1 (Kobayashi et al., 2009), and mouse embryonic fibroblasts derived from Keap1 C151 
transgenic animals (Yamamoto et al., 2008). However, the heavy metal arsenite 
(Wakabayashi et al., 2004) as well as prostaglandins prostaglandin A2 (PGA2) and 15d-PGJ2, 
can activate Nrf2 independent of Keap1 C151 (Kobayashi et al., 2009; Wang et al., 2008). 
These data suggests that Keap1 might have multiple sensing mechanisms for activation of 
Nrf2 and subsequent ARE-dependent gene expression. 
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2.3.1.2 Proposed mechanisms for Nrf2 activation  
It is evident that the modification of Keap1 cysteines leads to the accumulation of Nrf2 in 
the nucleus and expression of Nrf2 target genes. However, the mechanism for Nrf2 nuclear 
translocation is not fully understood but several models have been proposed. According to 
the first model for Nrf2 activation, it was thought that under basal conditions, Nrf2 was 
sequestered in the cytoplasm by the actin bound Keap1. During electrophilic stress, the 
modification of cysteine residues in Keap1 would release Nrf2 allowing it to translocate to 
the nucleus, bind to ARE and drive the expression of target genes (Dinkova-Kostova et al., 
2002). However, subsequently it was found that inducers were unable to dissociate Keap1-
Nrf2 binding (Eggler et al., 2005), and Nrf2 is rapidly ubiquitinated and degraded under 
basal conditions (Zhang & Hannink 2003) requiring novel models to be developed.  
 
 
Figure 9.  Mechanism for activation of Keap1-Nrf2-ARE-pathway. Two different motifs of Neh2 
domain of Nrf2 (red), DLG and ETGE motifs, bind Keap1 (blue) Kelch domain resulting in an 
Nrf2-Keap1 complex of 1:2 stoichiometry (B). Under basal conditions, Keap1 functions as an 
adaptor protein in the Cul3-based E3 ligase complex, resulting in rapid ubiquitination of the 
lysine residues located between the ETGE and DLG motifs, and subsequent degradation of Nrf2 
(C). Upon activation, electrophiles can directly bind Keap1 cysteines such as C151, C273 and 
C288 resulting in a conformational change in Keap1 leading to detachment of the weaker 
binding DLG motif and disturbed ubiquitination of Nrf2. In this setting, the Keap1-ETGE binding 
remains (Hinge and Latch model) (A). Alternatively, cysteine modifications in Keap1 lead to the 
dissociation of Keap1 and Cul3 (Keap1-Cul3 dissociation model) (D). In both models, Nrf2 
escapes the degradation pathway, translocates to the nucleus, binds to ARE, and promotes the 
transcription of several antioxidant genes such as NQO1, HMOX1, GCL and GSTs (E). Modified 
from (Kansanen, Jyrkkanen, & Levonen 2011) 
2.3.1.2.1 Dissociation of Keap1 and Cul3 
In basal conditions, Keap1 functions as an adaptor protein in the Cul3 (Cullin3) -based E3 
ligase complex, resulting in rapid ubiquitination and subsequent degradation of Nrf2 
(Cullinan et al., 2004; Kobayashi et al., 2004; Zhang et al., 2004) (Figure 9C). According to 
the Keap1-Cul3 dissociation model, the binding of Keap1 and Cul3 is disrupted in response 
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to electrophiles, leading to the escape of Nrf2 from the ubiquitination system (Figure 9D). 
This has been confirmed with various electrophiles including SFN (Wang et al., 2008; 
Zhang et al., 2004), IAB (Rachakonda et al., 2008), and tBHQ (Wang et al., 2008) but it has 
also been claimed that Nrf2 can be activated without the need for dissociation of Keap1 and 
Cul3 in response to Nrf2 activators including arsenite (Wang et al., 2008). Modifications of 
C151 appear to decrease Cul3 interactions, leading to inhibition of Keap1-dependent 
ubiquitination of Nrf2 (Zhang et al., 2004). It has been postulated that in addition to 
electrophile adduction to C151, a bulky modification, such as cysteine to tryptophan 
substitution, at this site would cause conformational changes that alter Cul3 binding 
allowing Nrf2 to escape proteosomal degradation (Eggler et al., 2009). When Nrf2 escapes 
the ubiquitination, it can translocates to the nucleus and drives target gene expression 
(Figure 9E).  
2.3.1.2.2 Hinge and latch model 
The Neh2 domain of Nrf2 has two different motifs that bind Keap1, the ETGE and the DLG 
motifs, and this results in a Keap1-Nrf2 complex with 1:2 stoichiometry with two binding 
sites in Nrf2 (Tong et al., 2006a) (Figure 9B). The two-site binding is beneficial for 
ubiquitination of Nrf2, because the lysine residues are aligned between the Keap1 binding 
ETGE and DLG motifs (Figure 8, 7Ks). According to the hinge and latch model, during 
electrophilic stress, modification of specific Keap1 cysteines leads to conformational 
changes in Keap1, resulting in the detachment of the weaker binding DLG motif from 
Keap1 (Latch). In this setting, ubiquitination of Nrf2 is disturbed but the binding with the 
ETGE motif remains (Hinge) (Tong et al., 2006b; Tong et al., 2006a; Tong et al., 2007) (Figure 
9A). Similar to the Keap1-Cul3 dissociation model, Nrf2 escapes the degradation and is able 
to translocate to the nucleus (Figure 9E).  
2.3.1.2.3 Other Nrf2 activation models 
In addition, Keap1 nucleocytoplasmic shuttling has been suggested as an alternative model 
for Nrf2 activation (Niture & Jaiswal 2009; Sun et al., 2007). According to this model, Keap1 
enters the nucleus and removes Nrf2 under both basal and induced conditions. The 
inducers inhibit the nuclear entry of Keap1 allowing the transcription of Nrf2-dependent 
genes (Baird & Dinkova-Kostova 2011). However, Keap1 is predominantly located in the 
cytoplasm and only 5% of Keap1 is present in the nucleus under both basal and induced 
conditions (Watai et al., 2007). This suggests that while nucleocytoplasmic shuttling may 
occur, it might not have a significant impact on the electrophile-induced activation of Nrf2. 
In addition, it has been proposed that in response to inducers, instead of Nrf2, Keap1 
becomes the target for ubiquitination (Hong et al., 2005; Zhang et al., 2005). Furthermore, 
multiple protein kinases have been implicated in the regulation of Nrf2 activity. For 
example, protein kinase C (PKC) can phosphorylate Nrf2 serine 40, which results in the 
release of Nrf2 from Keap1 leading to increased ARE-dependent gene expression (Bloom & 
Jaiswal 2003; Huang, Nguyen, & Pickett 2000). In addition, double-stranded RNA-activated 
protein kinase-like ER kinase (PERK) has been shown to phosphorylate Nrf2 resulting in 
nuclear accumulation of Nrf2 (Cullinan et al., 2003) Moreover, recent reports have detected 
novel proteins that compete with the binding of Nrf2 to Keap1. p21 protein binds to the 
DLG motif in Nrf2 and attenuates its rate of ubiquitination, leading to the stabilization of 
Nrf2  (Chen et al., 2009). In addition, sequestosome-1 has been shown to activate Nrf2 via 
an interaction with Keap1 through a motif within the C-terminal region resembling the 
ETGE motif in Nrf2 (Jain et al., 2010; Komatsu et al., 2010).  
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2.3.1.3 Target genes of Nrf2 
The target genes of Nrf2 contain an ARE sequence in their regulatory region (Rushmore, 
Morton, & Pickett 1991) and were identified by gene expression profiling of Nrf2 knockout 
(Nrf2-/-) mice (Kwak et al., 2003; Lee et al., 2003). These genes include detoxification 
enzymes such as NQO1 and GSTs, antioxidant enzymes including HO-1 and thioredoxin, 
as well as enzymes, such as GCL, involved in glutathione metabolism and recycling. 
Furthermore, Nrf2 activates proteosomal and chaperone proteins, indicating that Nrf2 has 
an important role also in regulating the reparation and removal of damaged proteins.  
2.3.1.3.1 NAD(P)H quinone oxidoreductase 1  
NQO1 is a major antioxidant enzyme that reduces quinones to hydroquinones preventing 
them from participating in oxidative cycling and in the generation of reactive oxygen 
intermediates. The gene expression of NQO1 is tightly regulated by Nrf2 and induced 
during oxidative or electrophilic stress  (Dinkova-Kostova & Talalay 2010). 
2.3.1.3.2 Heme oxygenase-1 
HO-1 is the rate-limiting enzyme in the oxidative degradation of cellular heme that 
liberates iron, carbon monoxide (CO), and biliverdin. Biliverdin is further converted to 
bilirubin by biliverdin reductase. HO-1 has a critical role in red blood cells as it breaks 
down heme in hemoglobin, but is expressed in other tissues as well. In tissues where HO-1 
is not directly needed for hemoglobin metabolism, the basal expression of HO-1 is low, but 
is extensively up-regulated by a wide variety of oxidative stress stimuli. Nrf2 is one of the 
transcription factors that regulate the expression of HO-1, but additional signaling 
pathways through multiple response elements present in HO-1 gene promoter are also 
important. HO-1 has many protective functions in the vascular system. In atherosclerosis, 
HO-1 can inhibit smooth muscle cell proliferation, monocyte migration, and inflammatory 
gene expression. The effects of HO-1 appear to be mediated by the end products CO and 
biliverdin (Wang & Chau 2010). In addition, increased HO-1 expression has been found in 
symptomatic atherosclerotic plaques compared to asymptomatic plaques in human 
patients. Intraplaque hemorrhages of symptomatic plaques were postulated as being the 
mechanism accounting for increased HO-1 expression (Ijas et al., 2007).  
2.3.1.3.3 Glutamate cysteine ligase 
GSH is an important antioxidant, which in healthy tissue primarily exists in its reduced 
form. During oxidative stress, GSH is oxidized to the disulfide form, glutathione 
hydrodisulfide (GSSG) by GPx in a reaction where a radical such as lipid hydroperoxide is 
reduced. GSSG is then reduced back to GSH by glutathione reductase. GCL catalyzes the 
rate limiting step in the synthesis of GSH. GCL is a heterodimeric protein composed of 
catalytic (GCLC) and modifier (GCLM) subunits that are coded by different genes. The two 
subunits are often coordinately induced in response to oxidative stress or electrophiles, but 
the post-translational modifications mediate differential levels of induction. GCLM is the 
limiting enzyme for the GCL dimer formation. The gene expression of GCLC and GCLM is 
regulated by multiple transcription factors including Nrf2, but also activator protein 1 and 
3, NF-κB, cAMP response element-binding, and others (Franklin et al., 2009). 
2.3.1.4 Role of Nrf2 in atherosclerosis 
The induction of Nrf2 regulated enzymes is generally regarded as protective in the vascular 
system. For example, in areas of high shear stress, where atherosclerotic lesions are less 
common, expression levels of Nrf2 regulated genes are elevated compared to low shear 
areas. Shear stress induced, Nrf2-dependent upregulation of HO-1, GCL, and NQO1 is 
shown in vitro in human endothelial cells as well as endothelial cells isolated from the wild 
type compared to Nrf2-/- mice (Chen et al., 2003; Fledderus et al., 2008; Hosoya et al., 2005). 
Furthermore, activation of Nrf2 by SFN reduces expression of VCAM-1 in low shear areas 
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in mouse aortas (Zakkar et al., 2009). ROS as well as lipid peroxidation products have been 
postulated to be involved in the increased activation of Nrf2 in high shear areas (Takabe, 
Warabi, & Noguchi 2011). Moreover, a reduced number of macrophages and lower levels of 
inflammatory chemokine MCP-1 were detected in Nrf2 transduced aortas of balloon-
denuded atherosclerotic rabbits (Levonen et al., 2007). In addition to protecting the vessel 
from inflammation, the activation of Nrf2 reduces smooth muscle cell proliferation in cell 
culture and diminishes the amount of oxLDL in the vessel wall in vivo after balloon 
angioplasty injury in rabbits (Levonen et al., 2007). 
These results strongly suggest that Nrf2 may have a protective role in the development 
of atherosclerosis. In an attempt to investigate this phenomenon in more detail, mouse 
models with a combination of an atherosclerotic background and Nrf2-/- have been 
developed. In contrast to expectations from the shear stress studies, current in vivo data 
indicates that lack of Nrf2 protects from diet-induced atherosclerosis in male mice in apoE-/- 
mouse model (Barajas et al., 2011; Freigang et al., 2011; Sussan et al., 2008). However, apoE-/- 
mice experience a dramatic accumulation of cholesterol-rich lipoproteins (very low density 
lipoprotein and chylomicrons) in the plasma, even on a low-fat diet. In addition, apoE-/- 
mice develop advanced atherosclerotic lesions at an early stage (Veniant et al., 2008) and 
may not be the best model to study the early events in atherosclerosis.  
2.3.2 Heat shock response 
In addition to the ARE-regulated stress response, cells have other integrated stress-
response pathways triggered by endogenous stimuli or environmental stresses. HSR is an 
ordered response to a wide array of acute and chronic stress conditions including heat, 
metabolic dysregulation, electrophiles, and exposure to inflammatory-derived reactive 
species. HSR is regulated at the transcriptional level by heat shock factors such as heat 
shock factor 1 (HSF1). HSF1 regulation is complex but it is suggested that chaperones 
HSP70 and heat shock proteins 90 kDa and 40 kDa (HSP90 and HSP40) have the potential 
to inhibit HSF1 and they keep HSF1 in an inactive form. Upon activation, HSF1 is released 
from the complexes and it undergoes multistep processing involving post-translational 
modifications, nuclear enrichment, trimerization, and binding to heat shock elements,  
resulting in transcription of a large family of heat shock genes. Many of the proteins 
encoded by heat shock genes function as chaperones, proteases, or other proteins essential 
for protection of the cell against proteotoxic stress (Richter, Haslbeck, & Buchner 2010). 
The electrophilic lipid peroxidation product 4-HNE (West & Marnett 2005) as well as 
two electrophiles SFN (Gan et al., 2010) and 15d-PGJ2 (Zingarelli et al., 2007) can facilitate 
cell protection by triggering the HSR. 4-HNE can alter the heat shock response by 
disrupting the inhibitory interaction of HSF1 and HSP70, which leads to the expression of 
the heat shock genes and HSF1-dependent activation of Bcl-2-associated athanogene 
domain mediated expression of antiapoptotic proteins Bcl-XL, Mcl1, and Bcl-2 that facilitate 
the protective effects (Jacobs & Marnett 2007). Electrophiles can attack nucleophilic residues 
in proteins and it is known that 4-HNE can directly bind to heat shock proteins HSP70 and 
HSP90 (Vila et al., 2008). Furthermore, specific cysteine residues, C572 in HSP90 and C267 
in HSP70 were identified as targets of 4-HNE (Carbone et al., 2004; Carbone et al., 2005). 
This may be the mechanism by which electrophilic compounds activate HSR. However, it 
remains to be investigated whether different electrophiles have unique activation 
mechanisms or targets in HPSs. In addition to redox sensitivity of HSPs, HSF1 contains 
cysteine residues that are critical in the homotrimer assembly (Ahn & Thiele 2003) as well 
as for DNA binding  (Lu et al., 2008). These cysteine residues can be modified by heat and 
hydrogen peroxide (Ahn & Thiele 2003; Lu et al., 2008), but there are no reports indicating 
that HSF1 is a direct target of electrophiles, nor is it known whether other electrophilic 
lipids in addition to 4-HNE can modify HSPs. 
  
22 
 
 
  
23 
 
 
3 Aims of the study 
Endogenous molecules oxPAPC and OA-NO2 are known to participate in cytoprotection in 
the vasculature. Nrf2 is recognized as a major transcription factor regulating the expression 
of cytoprotective enzymes. The aim of this thesis was to investigate the molecular 
mechanism by which oxPAPC and OA-NO2 take part in cytoprotection and regulate 
vascular function in endothelial cells with a special focus on Nrf2 signaling. 
 
The specific aims of this thesis were as follows: 
 
 
I  Investigate the Nrf2 activating capacity of oxPAPC in human endothelial cells 
and mouse carotid arteries and characterize the specific lipid species inducing 
Nrf2-regulated antioxidant enzymes.    
 
II Characterize the Nrf2-dependent and independent effects of OA-NO2 on gene 
expression in human endothelial cells using genome-wide transcriptional 
profiling. 
 
III Investigate the molecular mechanism by which OA-NO2 activates Nrf2 
focusing on the post-translational modifications of cysteine residues in the Nrf2 
inhibitor Keap1 by nitroalkylation and its downstream effects. 
 
IV Identify the role of Nrf2 in the regulation of transcription of ETB.  
 
  
24 
 
 
  
25 
 
 
4 Materials and methods 
4.1 SUMMARY OF THE MATERIALS AND METHODS 
The materials and methods used in this study are summarized in the following tables. The 
detailed descriptions of the methods used are presented in the original publications (I–III) 
and the manuscript (IV). 
 
Table 1. Summary of the methods used in this study 
Method Description Original article 
DNA cloning 
Construction of luciferase reporter vectors 
Construction of overexpressing vectors 
Construction of vector for adenoviral overexpression  
I, II, III 
III 
IV 
Cell culture 
Cell line culture 
Human umbilical vein endothelial cell isolation 
Mouse heart and lung endothelial cell isolation 
I, II, III, IV 
I, II, III, IV 
IV 
Cell biology methods 
Chemical treatment with compounds presented in 
Table 3  
Luciferase reporter assay 
siRNA-transfection assay 
Protein-protein binding assay 
Transduction of adenoviral vectors 
I, II, III, IV  
 
I, II, III 
I, II, III, IV 
III 
IV 
In vivo methods 
Application of oxPAPC to carotic arteries 
Anesthesia, sacrifice, tissue collection 
Fixation, embedding, sectioning 
I 
I 
I 
Methods to study gene 
expression 
RNA isolation 
Quantitative real-time polymerase chain reaction 
(qPCR) 
Affymetrix microarray analysis and data handling 
I, II, III, IV 
I, II, III, IV 
 
II 
Methods to study protein 
expression 
Measurement of total protein concentration 
Extraction of nuclear and cytoplasmic proteins 
Western blot 
Immunohistochemistry 
I, II, III, IV 
I, II 
I, II, III, IV 
I 
Immunoprecipitation 
methods 
Chromatin immunoprecipitation 
Immunoprecipitation 
I, II, III, IV 
III 
MS based methods 
LC/MS detection and analysis of Keap1 post-
translational modifications 
Analysis and quantification of β-ME adducts 
 
III 
III 
Other analysis methods 
β-galactosidase staining 
PCR of the chromating templates 
I, II, III 
I, II, IV 
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Table 2. Plasmids and viral vectors used in this study 
Construct Description Origin 
Original 
article 
pGL3-SV40-luciferase 
Luciferase reporter construct with 
luciferase cDNA under SV40 promoter 
Promega I, II, III 
pGL3-SV40-NOQ1-
ARE-luciferase 
Luciferase reporter construct with one 
ARE of NQO1 gene  
H.Leinonen, University 
of Eastern Finland, 
Kuopio, Finland 
I, II 
pGL3-SV40-mut-
NQO1-ARE-luciferase 
Luciferase reporter construct with 
mutated ARE of NQO1 gene 
H.Leinonen I, II 
pGL3-SV40-2xGCLM-
ARE-luciferase 
Luciferase reporter construct with two 
AREs of GCLM gene 
H.Leinonen III 
pCMV-β-gal β-galactosidase under CMV promoter Invitrogen I, II, III 
pCI CI plasmid with CMV promoter Promega III 
pCI-Nrf2 CI plasmid with Nrf2 cDNA  
R.T.Mulcany, 
University of 
Wisconsin Medical 
School, Madison, 
Wisconsin 
III 
p3xFLAG-CMV 
Empty FLAG plasmid with three FLAG 
epitopes under CMV promoter 
Sigma III 
p3xFLAG-mKeap1-wt 
FLAG plasmid with mouse wild type 
Keap1 cDNA  
A-L.Levonen, 
University of Eastern 
Finland, Kuopio, 
Finland 
III 
p3xFLAG-mKeap1-
C38S 
FLAG plasmid with mouse Keap1 cDNA 
with Cys38 to Ser modification 
E.Kansanen, 
University of Eastern 
Finland, Kuopio, 
Finland 
III 
p3xFLAG-mKeap1-
C151S 
FLAG plasmid with mouse Keap1 cDNA 
with Cys151 to Ser modification 
A-L.Levonen III 
p3xFLAG-mKeap1-
C257S 
FLAG plasmid with mouse Keap1 cDNA 
with Cys257 to Ser modification 
E.Kansanen III 
p3xFLAG-mKeap1-
C273S 
FLAG plasmid with mouse Keap1 cDNA 
with Cys273 to Ser modification 
A-L.Levonen III 
p3xFLAG-mKeap1-
C288S 
FLAG plasmid with mouse Keap1 cDNA 
with Cys288 to Ser modification 
A-L.Levonen III 
p3xFLAG-mKeap1-
C489S 
FLAG plasmid with mouse Keap1 cDNA 
with Cys489 to Ser modification 
E.Kansanen III 
HA-Cullin3 HA plasmid expressing human Cullin3 H.Leinonen III 
AdCMV Empty adenovirus with CMV promoter 
M.Päivärinta, 
University of Kuopio, 
Finland 
IV 
AdNrf2 
Adenovirus expressing human Nrf2 
under CMV promoter 
A-L.Levonen IV 
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Table 3. Key compounds used in this study 
Compound Description Origin 
Original 
article 
PAPC 1-palmitoyl-2-arachidonoyl-3-phosphatidyl choline Avanti I 
DMPC 1,2-dimyristoyl-sn-glycero-3-phosphocholine  Avanti I 
PAPG 
1-palmitoyl-2-arachidonoyl-sn-glycero-3-
phosphoglycerol 
Avanti I 
PAPA 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphate Avanti I 
PAPE 
1-palmitoyl-2-arachidonoyl-sn-glycero-3-
phosphatidylethanolamine 
Avanti I 
PAPS 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphoserine Avanti I 
LysoPC 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine Avanti I 
POVPC 
1-palmitoyl-2-(5-oxovaleroyl)-sn-glycero-3-
phosphocholine 
V.Bochkov, 
Medical 
Univeristy of 
Vienna  
I 
PGPC 1-palmitoyl-2-glutaroyl-sn-glycero-3-phosphocholine V.Bochkov I 
PEIPC 
1-Palmitoyl-2-(5,6-epoxy isoprostane E2)-sn-glycero-3-
phosphocholine 
V.Bochkov I 
PLPC 1-palmitoyl-2-linoleoyl-sn-glycero-3-phosphocholine Avanti I 
PAPCOOH 
1-palmitoyl-2-(12-hydroperoxyeicosa-5,8,10,14-
tetraenoyl)-sn-glycero-3-phosphocholine and 1-
palmitoyl-2-(15-hydroperoxyeicosa-5,8,11,13-
tertraenoyl)-sn-glycero-3-phosphocholine 
V.Bochkov I 
NAC N-acetyl cysteine Sigma I 
GSH Glutathione Sigma I 
OA-NO2 9- and 10-nitro-octadec-9-enoic acid 
S.Woodcock, 
University of 
Pittsburgh, 
PA 
II-IV 
9-OA-NO2 9-nitro-octadec-9-enoic acid S.Woodcock III 
10-OA-NO2 10-nitro-octadec-9-enoic acid S.Woodcock III 
15d-PGJ2 15-deoxy-Δ12,14-prostaglandin J2 Chemicon III 
SFN L-sulforaphane Sigma III 
ET-1 Endothelin 1 Sigma IV 
 
 
Table 4. TaqMan gene expression assays used in this study   
Gene TaqMan® Gene 
Expression Assay 
Original 
article 
HO-1 Heme oxygenase (decycling) 1 Hs00157965_m1, I, II 
HO-1 Heme oxygenase (decycling) 1 Mm00516004_m1 I 
GCLM Glutamate-cysteine ligase, modifier subunit Hs00157694_m1, I, II 
GCLM Glutamate-cysteine ligase, modifier subunit Mm00514996_m1 I 
NOQ1 NAD(P)H dehydrogenase, quinone 1 Hs00168547_m1, 
 
I, II 
NOQ1 NAD(P)H dehydrogenase, quinone 1 Mm00500821_m1 I 
Nrf2 Nuclear factor (erythroid-derived 2)-like 2 Hs00232352_m1 I, II, IV 
HSPA1A Heat shock 70kDa protein 1A;heat shock 70kDa 
protein 1B 
Hs00359147_s1 II 
DNAJA4 DnaJ (Hsp40) homolog, subfamily A, member 4 Hs00388055_m1 II 
HSPB8 Heat shock 22kDa protein 8 Hs00205056_m1 II 
HSPA6 Heat shock 70kDa protein 6 (HSP70B')  Hs00275682_s1 II 
HSF1 Heat shock transcription factor 1 Hs00232134_m1 II 
EDNRB Endothelin receptor type B Hs00240747_m1 IV 
Abbreviations used: Hs, human assay; Mm, mouse assay 
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Table 5. Primary antibodies used in this study  
Antibody Description Application Manufacturer 
Original 
article 
Nrf2 Rabbit polyclonal anti-Nrf2 Ab WB Santa Cruz (#sc-13032) I, II 
Nrf2 Rabbit polyclonal anti-Nrf2 Ab ChIP Santa Cruz (#sc-722) I, II, III, IV 
HO-1 Rabbit polyclonal anti-HO-1 Ab WB, ICH Stressgen (#SPA-896) I, II 
GCLM Rabbit polyclonal anti-GCLM Ab WB 
From Dr. Terrance 
Kavanagh, 
University of Washington, 
Seattle 
I, II 
NQO1 
Mouse monoclonal Ab, clones 
A180 and B771 
WB 
From Dr. David Ross, 
University 
of Colorado, Denver 
I, II 
NQO1 Rabbit polyclonal anti-NOQ1 Ab ICH Abcam I 
HSF1 Rabbit polyclonal anti-HSF1 Ab WB Cell Signaling (#4356) II 
HSF1 Rabbit polyclonal anti-HSF1 Ab ChIP Stressgen (#SPA-901) II 
HSP70 
Mouse monoclonal anti-
HSP70/72 Ab 
WB Stressgen (#SPA-810) II 
FLAG 
Mouse monoclonal anti-FLAG 
M2 Ab, HRP conjugated 
WB Sigma (#A8592) III 
FLAG Anti-FLAG affinity gel IP Sigma (#A2220) III 
HA 
Mouse monoclonal anti-HA.11 
Ab 
WB, IP Covance (#MMS-101P) III 
β-actin 
Rabbit polyclonal anti-β-actin 
Ab 
WB Cell Signaling (#4967L) I, II, III, IV 
Abbrevation used: ChIP, Chromatin immunoprecipitation; WB, Western blot; ICH, 
Immunohistochemistry; Ab, Antibody 
 
 
Table 6. Cell lines and culture condition used in this study. 
Cell line Description Source Culture conditions 
Original 
article 
HUVEC 
Human umbilical 
vein endothelial 
cells 
Primary cells isolated from 
umbilical cords obtained 
from maternity ward of 
Kuopio University hospital 
EBM endothelial medium 
supplemented with EGM 
bullet kit 
I, II, III, IV 
HAEC 
human aortic 
endothelial cells 
Primary endothelial cells 
isolated from human aorta 
purchased from Lonza 
EGM2 bullet kit IV 
HASMC 
human smooth 
muscle cell line 
Primary human aortic 
smooth muscle cells 
purchased from Lonza 
Medium 231 
supplemented with SMGS 
IV 
MLEC, 
MHEC 
mouse endothelial 
cell line from lung 
or heart 
Primary cells isolated from 
mouse lungs or hearts 
DMEM, 20% FBS, 50 
U/ml penicillin, 50 µg/ml 
streptomycin, 20 mM 
HEPES, 1/100 NEAA, 
1/100 Sodium pyruvate, 
1 mM L-glutamine, 0.1 
mg/ml endothelial 
mitogen, 0.1 mg/ml 
heparin 
IV 
HEK-293T 
human embryonic 
kidney cell line 
The American Type Culture 
Collection (ATCC) 
DMEM, 10% FBS, 50 
U/ml penicillin, 50 µg/ml 
streptomycin 
III 
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Table 7. siRNAs and their sequences used in this study 
siRNA Sequence Original article 
Nrf2-siRNA-1 5´-UAAAGUGGCUGCACAGAAUTT-3´ I, II, IV 
Nrf2-siRNA-2 5´-UGACAGAAGUUGACAAUUA-3´ II 
HSF-1-siRNA-1 5´-GCUCAUUCAGUUCCUGAUCTT-3´ II 
HSF-1siRNA-2 5´-CGGAUUCAGGGAAGCAGCUGGUGCATT-3´ II 
siControl 5´-UUCUCCGAACGUGUCACGUTT-3´ I, II, IV 
 
 
Table 8. Primers used in PCRs of chromatin templates 
Gene Forward primer  Reverse primer 
Original 
article 
HMOX1 CCATCTGGCGCCGCTCTGC GAGCAGCTGGAACTCTGAGGA I 
NQO1 AAGTGTGTTGTATGGGCCCC TCGTCCCAAGAGAGTCCAGG I 
Control* ATCTATGTGGCCCTGGAGGAG TCGTGGAGCCGCTTCACATAG I 
HSP70 CCATGGAGACCAACACCCT CCCTGGGCTTTTATAAGTCG II 
actin AACTCTCCCTCCTCCTCTTCCTC GAGCCATAAAAGGCAACTTTCGG II 
HMOX1 TGAGTAATCCTTTCCCGAGC GTGACTCAGCGAAAACAGACA III 
* nonspecific binding site from HMOX1 exon3 
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5 RESULTS 
5.1 oxPAPC AND OA-NO2 ACTIVATE NRF2 REGULATED EXPRESSION OF 
ANTIOXIDANT ENZYMES IN HUMAN ENDOTHELIAL CELLS (I, II) 
On activation, Nrf2 protein accumulates to the nucleus, binds to the ARE, and drives the 
expression of ARE-regulated genes such as HO-1, GCLM and NQO1 (Kansanen, Kivela, & 
Levonen 2009). The ability of both oxPAPC and OA-NO2 to activate Nrf2 was investigated 
in human umbilical vein endothelial cells (HUVECs) and both compounds significantly 
increased the expression of the three selected target genes, HO-1, GCLM and NQO1 (Figure 
1 in Publication I; and Figure 1 in Publication II). A small interfering RNA (siRNA) 
approach was utilized to study whether oxPAPC and OA-NO2 could induce the expression 
of these antioxidant genes in an Nrf2-dependent manner. The silencing of Nrf2 resulted in 
decreased expression of all three selected target genes both under basal conditions as well 
as in oxPAPC or OA-NO2 treated conditions both at the mRNA (Figure 10) and protein 
levels (Figure 11) compared to vehicle (control), or in the case of OA-NO2, also compared to 
the fatty acid control, OA (Figure 10B). 
 
Figure 10. Inhibition of Nrf2 blocks oxPAPC and OA-NO2 induced HO-1, GCLM and NQO1 mRNA 
expression. HUVECs were transfected with control or Nrf2 siRNA and 24 h after transfection, 
cells were treated with vehicle (control) 50 µg/ml oxPAPC (A), 3 µM OA-NO2, or 3 µM OA (B) for 
8 h. The expression of Nrf2, HO-1, GCLM and NQO1 was determined with qPCR. Values are 
represented as mean +/- SEM (n=3), * p<0.05 versus control.  
 
In addition to the Nrf2-dependent increase in HO-1, GCLM and NQO1 mRNA and 
protein expression, both oxPAPC and OA-NO2 were able to promote the nuclear 
translocation of Nrf2 (Figure 1A in Publication I; and Figure 11 A–B), which is a critical step 
in the activation process of ARE-regulated antioxidant enzymes. Furthermore, almost 90% 
silencing of Nrf2 expression at both the mRNA (Figure 10) and protein levels (Figure 11A) 
was detected after transfection with Nrf2 siRNA demonstrating that Nrf2 siRNA is a 
powerful tool when studying Nrf2-dependent cell signaling actions. 
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Figure 11. Inhibition of Nrf2 blocks oxPAPC and OA-NO2 induced HO-1, GCLM and NQO1 protein 
expression. HUVECs were transfected with control or Nrf2 siRNA and 24 h after transfection, 
cells were treated with 50 µg/ml oxPAPC (A, C) or 3 µM OA-NO2 (B, D) for 4 h (A–B) or 16 h (C 
- D). A–B. The nuclear and cytoplasmic extracts were isolated and the expression of Nrf2 was 
measured with Western blot. C–D. After treatment, the expression of Nrf2, HO-1, GCLM and 
NQO1 was determined with Western blot. Blots are representative of three independent 
experiments. 
5.2 OXPAPC INDUCES THE EXPRESSION OF ANTIOXIDANT GENES IN 
MURINE ARTERIES (I) 
To study the effects of oxPAPC in vivo, oxPAPC in pluronic gel was applied to the 
adventitial side of surgically exposed carotid arteries of either wild type (WT) C57BL/6 
controls or Nrf2-/- mice. oxPAPC induced both RNA (Figure 6 in Publication I) and protein 
expression (Figure 12) of Nrf2 target genes HO-1 and NOQ1 in vivo. HO-1 expression in 
oxPAPC-treated arteries in WT but not in Nrf2-/- arteries was localized mainly in the 
adventitia of the vessels (Figure 12, left panel). The expression of NQO1 protein was more 
uniformly increased throughout the vessel wall in oxPAPC treated WT carotid arteries, 
with increased positive staining in the adventitial and medial layers and especially in the 
endothelial layer (Figure 12, right panel).  
Figure 12. OxPAPC activates Nrf2 target genes in vivo in mouse carotid arteries. Carotid arteries 
of WT and Nrf2-/- mice were surgically exposed and covered with 30% pluronic gel with or 
without 50 µg oxPAPC for 24 h. The protein expressions of HO-1 and NQO1 were studied. 
Arrowhead indicates HO-1 positivity. Original magnification, x400. Scale bars 50 µm. L indicates 
lumen; M, media, A, adventitia. 
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5.3 ELECTROPHILIC PROPERTIES ARE REQUIRED FOR NRF2 
ACTIVATION (I, III) 
5.3.1 Electrophilic sn-2 side chain in oxidized phospholipids is critical for activation of 
Nrf2 target genes (I) 
When studying the effects of phospholipids in the vascular system, the aim was to 
characterize in more detail which structures in oxPAPC are essential to activate Nrf2. In the 
sn-3 position, PAPC has a PC as a polar head goup. In addition, PAPC has two fatty acid 
side chains, palmitic acid in sn-1 and arachidonic acid in sn-2 position. First, the effect of 
polar head groups in the sn-3 position on Nrf2 activation were studied. Since oxPAPC 
increased the expression of both GCLM and NQO1 in an Nrf2-dependent manner (Figure 
10A), they were chosen as markers of Nrf2 activation. The replacement of PC of oxPAPC to 
phosphatidyl glycerol (PG), phosphatidic acid (PA), PE, or PS did not change the GCLM 
and NQO1 activating property of the phospholipid suggesting that the polar group in sn-3 
position does not play any role in the activity (Figure 13A). 
Next, the significance of the sn-2 fatty acid side chain was investigated by treating the 
cells with LysoPC, a lipid in which only a hydroxyl group in in sn-2 position is present. 
Because neither LysoPC (Figure 13B) nor unoxidized lipids (Figure 13A) were able to 
induce the expression of GCLM or NQO1, it was found that the presence of an oxidized  
sn-2 residue is critical for the activation of the two selected Nrf2 regulated genes. Oxidative 
modification of the sn-2 side chain in PAPC yields fragmented lipid species such as POVPC 
and PGPC, and oxygenated species such as PEIPC (Figure 6). Next, the ability of these 
lipids to activate GCLM and NQO1 was tested. Fragmented oxidation products PGPC and 
POVPC were not able to activate Nrf2 targets GCLM and NQO1 (Figure 13C), whereas 
PEIPC (Figure 13D) as well as the hydroperoxide group containing form of oxygenated 
PAPC, PAPCOOH (Figure 13E), were potent in activating GCLM and NQO1. These results 
demonstrated the critical importance of an oxidized sn-2 residue in the activation of Nrf2 as 
well as identifying PEIPC and PAPCOOH as specific molecular species capable of 
activating GCLM and NQO1.  
In and attempt to test the role of electrophilic groups present in oxPAPC, these were 
reduced with sodium borohydrate (NaBH4). Treatment of oxPAPC with NaBH4 partially 
suppressed the induction of GCLM and NQO1. Furthermore, coincubation of oxPAPC, 
PAPCOOH or PEIPC with nucleophilic thiol antioxidants like N-acetylcysteine (NAC) and 
GSH reduced the induction of both GCLM and NQO1 as well as HO-1 (Figure 13G–I). 
Furthermore, the coincubation of PEIPC with NaBH4 totally abolished the induced 
expression of HO-1, GCLM and NQO1 (Figure 13I). These data indicate that the 
electrophilic character of oxPAPC and its active components are largely responsible for 
mediating the effect on Nrf2-responsive genes. 
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Figure 13. The electrophilic sn-2 side chain is critical for activation of Nrf2 target genes. A–F. 
HUVECs were treated with native or oxidized PAPC, PAPG, PAPA, PAPE, or PAPS for 6 h. B–F. 
HUVECs were treated with oxPAPC (B–D), LysoPC (B), POVPC, PGPC (C), PEIPC (D), PAPCOOH, 
PAPCOH (E), mock or NaBH4 treated oxPAPC (F) for 6 h. After treatments, the expression of 
GCLM and NQO1 was determined with qPCR. G–H. HUVECs were exposed to oxPAPC or 
PAPCOOH in the presence of absence or NAC, and the protein expression of HO-1, GCLM and 
NQO1 were measured with Western blot. I. HUVECs were exposed to PEIPC in the presence of 
absence or NaBH4 or NAC and the mRNA expression of HO-1, GCLM and NQO1 was measured 
with qPCR. The qPCR results are expressed as mean +/- SEM (n=3 to 4). * p<0.05 GCLM vs. 
control, # p<0.05 NQO1 vs. control (A–F). ), * p<0.05 PEIPC vs. NaBH4 treated PEIPC, # 
p<0.05 PEIPC vs. PEIPC + NAC (I).The Western blots are representative of three independent 
experiments.  
5.3.2 OA-NO2 binds directly to nucleophilic residues in Keap1 (III) 
Post-translational modification of Keap1 mediates electrophile-induced signaling and 
allows the nuclear location of Nrf2 and ARE-dependent transcription. Electrophiles can 
directly form adducts with nucleophilic amino acids such as cysteines in Keap1. The 
adduction of OA-NO2 and Keap1 was studied with a MS approach and it was found that 
OA-NO2 directly bound to recombinant Keap1 at cysteine residues C38, C226, C273, C288, 
and C489 (Table 1 in Publication III). In addition to recombinant Keap1 protein, OA-NO2 
was able to directly bind to Keap1 also in cellular environment assessed with a MS-based 
method where the amount of OA-NO2-Keap1 adducts are quantified after an exchange 
reaction with exogenously added β-ME (Figure 14A). These results indicate that 
elecrophilic character of OA-NO2 is required for Keap1 modification and subsequent Nrf2 
and ARE activation. 
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5.4 OA-NO2 ACTIVATES NRF2 INDEPENDENT OF KEAP1 C151 (III) 
The activation of Nrf2 is tightly regulated by the inhibitor protein Keap1. Keap1 cysteine 
residues are known targets of electrophiles. In addition, Keap1 C273 and C288 are known 
to be required for Keap1 to inhibit Nrf2 while Keap1 C151 is critical in Nrf2-dependent 
ARE-activation. The molecular mechanism by which OA-NO2 activates Nrf2 was 
investigated by using MS as the first approach to examine the sites of recombinant Keap1 
adduction by OA-NO2. The analysis revealed that C38, C226, C273, C288, and C489, but not 
C151, were modified with the lowest OA-NO2 concentration used (Table 1 in Publication 
III). Keap1 C151 is important for facilitating Nrf2 activation by the electrophiles tBHQ and 
SFN (Wang et al., 2008; Zhang et al., 2004), but there are reports demonstrating that Nrf2 
can be activated independent of Keap1 C151 (Kobayashi et al., 2009; Wang et al., 2008). For 
this reason, the functional importance of Keap1 C151 in the activation of ARE in response to 
OA-NO2 was investigated, and the results reveal that like 15d-PGJ2 (Kobayashi et al., 2009), 
OA-NO2 can activate ARE independent of Keap1 C151 in the luciferase reporter assay 
(Figure 14B). 
 
Figure 14. OA-NO2 binds directly to Keap1, can activate ARE independent of Keap1 C151, and 
does not cause dissociation of Keap1 and Cul3. A. HEK-293T cells were transfected with FLAG-
CMV (empty) or FLAG-Keap1-overexpressing vector and treated with indicated concentrations of 
OA-NO2. Keap1 adducted with OA-NO2 was exchanged to β-ME from immunoprecipitated Keap1 
in the presence of [13C18]OA-NO2 internal standard and quantified by LC-MS/MS as β-ME-OA-
NO2. The lower panel shows the transfection efficiency. B. HEK-293T cells were co-transfected 
with the ARE-luciferase reporter vector, Nrf2 overexpressing vector, and a vector expressing 
wild type Keap1 or Cys to Ser mutation of the C151 residue. 24 h after transfection, cells were 
treated with 5 µM OA-NO2, 15d-PGJ2 or SFN, and the luciferase activity was measured. The 
results were normalized to β-galactosidase and presented as fold change versus pGL3-SV40-
control vector for each treatment. Values are represented as mean +/- SD, *** p < 0.001 when 
compared to ARE-luc + Nrf2 + Keap1-wt. C. HEK-293T cells were co-transfected with FLAG-
Keap1 and HA-Cul3 expressing vectors and treated with 5 µM OA-NO2, 15d-PGJ2 and SFN. Cell 
lysates were immunoprecipitated (IP) with FLAG or HA antibodies and the amount of bound 
Keap1 or Cul3 was determined with Western blot with FLAG or HA antibodies. The bottom figure 
shows the transfection efficiency of total cell lysates (input). Western blots are representative of 
three independent experiments.  
 
Keap1 functions as an adaptor protein in the Cul3-based E3 ligase complex and 
facilitates the ubiquitination and degradation of Nrf2 under basal conditions. When the 
concentration of cellular electrophilic species are elevated, the interaction of Nrf2 and the 
ubiquitin ligase system is disrupted enabling the escape of Nrf2 from degradation. 
According to the Keap1-Cul3 dissociation model, electrophilic adduction of Keap1 C151 
modulates the interaction of Keap1 and Cul3, leading to the concept that modification of 
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C151 may dissociate Keap1 from Cul3 and promote the escape of Nrf2 from proteosomal 
degradation (Cullinan et al., 2004; Kobayashi et al., 2004; Zhang et al., 2004). The binding of 
Keap1 and Cul3 is indeed diminished when cells were treated with SFN, whereas OA-NO2 
and 15d-PGJ2 enhanced the binding of the two proteins (Figure 14C). These results show 
that OA-NO2 can activate Nrf2 by a Keap1 C151-independent manner without dissociation 
of Keap1 and Cul3. 
5.5 OA-NO2 ACTIVATES THE HEAT SHOCK RESPONSE IN ENDOTHELIAL 
CELLS INDEPENDENT OF NRF2 (II) 
In addition to the Keap1-Nrf2-ARE pathway, Nrf2 inducers can activate other stress 
signaling pathways. To characterize Nrf2-dependent and -independent effects of OA-NO2 
on gene expression in human endothelial cells, a genome-wide transcriptional profiling 
utilizing Nrf2-siRNA was used. The data analysis revealed that in response to OA-
NO2 treatment, 362 genes were upregulated and 103 were downregulated (Figure 3A in 
Publication II). However, only 31 of the upregulated genes were also repressed by Nrf2-
siRNA, indicating that most of OA-NO2 induced genes where regulated by other factors 
than Nrf2 (Figure 4 and Supplemetary Table 1 In Publication II). In an attempt to identify 
which other factors might regulate OA-NO2 responsive genes, a Gene Set Enrichment 
Analysis was used. The analysis showed that 50% of enriched binding sites were HSF1 or 
HSF2 binding sites demonstrating that HSR is a major pathway activated by OA-NO2. In 
fact, 22 of the 50 most upregulated genes in response to OA-NO2 were heat shock related 
genes (Figure 3B in Publication II). These genes included well-characterized HSF target 
genes such as HSPA1A, DNAJA4, HSPB8 and HSPA6 (Figure 6 in Publication II). 
Furthermore, the data validation showed that OA-NO2 was able to induce the expression of 
HSPA1A and protein encoded by this gene, HSP70, in a HSF1-dependent manner. (Figure 
15A - B). Furthermore, OA-NO2 induced the binding of HSF1 to the HSE element located in 
the promoter area of HSP70 gene (Figure 15C). 
Interestingly, the data analysis showed that silencing of Nrf2 had no impact on basal or 
inducible expression of HSF target genes. The same effect was also demonstrated with ChIP 
where siNrf2 had no impact on HSF1 binding to HSE of HSP70 gene (Figure 7D in 
Publication II). These results demonstrated that while OA-NO2 can induce both the Nrf2-
pathway and HSR, these pathways are independent of each other.      
 
 
 
Figure 15. OA-NO2 induces HSP70 expression via HSF1. A–B. HUVECs were transfected with 100  
nM control or HSF1 siRNA. 72 h after transfection, cells were treated with 3µM OA-NO2 for 4 h 8 
h or with heat shock for 30 min. The expression of HSF1 and HSP70 (HSPA1A) was measured 
with qPCR. Values are expressed as mean+/-SEM, n=3. *, p<0.05 versus control. C, HUVECs 
were treated with 5µM OA-NO2 for 4 h. The binding of HSF1 to the promoter region of HSP70 
was determined with ChIP using β-actin as a control.  
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5.6 OA-NO2 INDUCES ETB EXPRESSION VIA NRF2 IN ENDOTHELIAL 
CELLS (IV) 
The genome-wide gene expression analysis examined whether where Nrf2-dependent and -
independent responses were activated after exposure to OA-NO2 (Publication II). This 
revealed that the gene encoding ETB was induced by OA-NO2 in Nrf2-dependent manner. 
ETB is a receptor for ET-1 and regulates blood pressure. Stimulation of ETB has a dual role in 
the vasculature. ETB receptors located in the endothelial cell can promote vascular 
relaxation while stimulus of ETB receptors in vascular smooth muscle cells contracts the 
vessels (Schneider, Boesen, & Pollock 2007). Here, the effects of OA-NO2 were investigated 
in HUVECs and in HAECs where a siRNA approach was used to silence Nrf2 in the cells. 
In addition, endothelial cells isolated from wt or Nrf2-/. mouse heart (MEC) were used. 
These cells were treated with OA-NO2 and the mRNA expression of ETB was measured. 
The result shows that ETB expression is robustly induced by OA-NO2 and that the lack of 
Nrf2 abolishes the induction indicating that the OA-NO2 induced expression of ETB is very 
tightly regulated by Nrf2 (Figure 16).    
 
 
 
Figure 16. OA-NO2 induces ETB expression in Nrf2-dependent manner. A–B. HUVEC and HAECs 
were transfected with conrol or Nrf2 siRNA and 24 h after transfection, cells were treated with 
vehicle (no treatment) 3 µM OA-NO2 for 8 h. C. MEC isolated from wt of Nrf2
-/- mouse heart 
were treated with 3 µM OA-NO2 for 8 h. The expression of ETB was determined with qPCR. 
Values are represented as mean +/- SEM (n=3), ** p<0.01, *** p<0.001 versus control.  
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6 DISCUSSION 
6.1 OXIDIZED AND NITRATED LIPIDS AS SIGNALING MEDIATORS 
Lipid oxidation and nitration products are formed in the progression of inflammation 
related diseases such as atherosclerosis. These species are often electrophiles that can post-
translationally modify proteins inducing not only toxic signaling actions, but also acting as 
signaling molecules to regulate specific signaling cascades (Rudolph & Freeman 2009).  
Under normal conditions, PAPC is a major phospholipid present in the surface lipid layer 
of LDL particle. Oxidation of the unsaturated arachidonic acid in sn-2 position of PAPC 
yields a wide variety of oxidation products of PAPC including PEIPC and PAPCOOH. In 
addition to pro-atherogenic properties such as induction of adhesion molecules and 
chemokines as well as promotion of monocyte binding to endothelial cells, oxPAPC can act 
as an anti-inflammatory mediator in the vasculature by blocking LPS induced inflammation 
(Leitinger et al., 1999) and by induction of HO-1 expression (Kronke et al., 2003). Nitro-fatty 
acids are endogenous lipid species formed in reactions of unsaturated fatty acids and 
reactive nitrogen species (Rubbo et al., 1994). The amounts of nitro-fatty acids are elevated 
in inflammatory conditions (Nadtochiy et al., 2009; Rudolph et al., 2010b). Nitro-fatty acids 
are known to be protective in several vascular disease models in vivo (Cole et al., 2009; 
Rudolph et al., 2010a; Rudolph et al., 2010b). 
In this thesis, both oxPAPC and OA-NO2 induced the expression of cytoprotective 
enzymes HO-1, GCLM and NOQ1 in human primary endothelial cells and oxPAPC also in 
murine arteries. Keap1-Nrf2-ARE signaling pathway was found to mediate the induction of 
these enzymes. In Keap1-Nrf2-ARE pathway, Keap1 is the sensor molecule that responds to 
stimuli such as electrophiles and ROS allowing transcription factor Nrf2 to translocate to 
the nucleus, bind to ARE, and drive the expression of antioxidant and cytoprotective 
enzymes (Baird & Dinkova-Kostova 2011). In addition, phosphorylation of Nrf2 by PKC or 
PERK demonstrate an alternative activation mechanism for triggering Nrf2-dependent 
expression (Bloom & Jaiswal 2003; Cullinan & Diehl 2004; Huang, Nguyen, & Pickett 2000). 
In the present study, direct binding of OA-NO2 and Keap1 cysteines is demonstrated 
revealing that Keap1 cysteine modification is the mechanism for Nrf2 activation by OA-
NO2. OA-NO2 is an electrophile and therefore it is not surprising that it directly reacts with 
the nucleophilic cysteine residues in Keap1 (Figure 17).  
OxPAPC activated antioxidant enzymes in a similar manner as OA-NO2, but the specific 
activation mechanism remains to be investigated. Nox-dependent production of ROS is 
suggested as a mechanism for Nrf2 activation by oxPAPC (Li et al., 2007; Rouhanizadeh et 
al., 2005). However, the limitation of these reports is the use of diphenyleneiodonium (DPI) 
as an inhibitor of Nox. The fact that DPI inhibits flavoenzymes in general, including Nrf2 
target genes such as NQO1, makes it difficult to interpret the results where DPI has been 
used. Furthermore, PERK-mediated phosphorylation of Nrf2 might serve as a mechanism 
for activation of Nrf2-dependent expression by oxPAPC. Involvement of PERK-dependent 
phosphorylation is not directly shown, but treatment with oxPAPC leads to ER stress and 
activation of unfolded protein response (UPR) (Gargalovic et al., 2006a). In addition, 
activation of UPR can result in PERK-dependent phosphorylation of Nrf2 leading to 
activation and nuclear translocation of Nrf2 (Cullinan et al., 2003). However, whether PERK 
can phosphorylate Nrf2 in response to oxPAPC was not directly studied here but it might 
serve as a mechanism for Nrf2 activation by oxPAPC.  
In this thesis, the critical role of an electrophilic sn-2 side chain in oxPAPC for the 
activation of Nrf2-dependent gene expression was revealed. PEIPC and PAPCOOH were 
identified as the lipid species activating antioxidant genes GCLM and NQO1. Both of these 
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species are electrophilic and the reduction with NaBH4, NAC or GSH abolished the induced 
expression of GCLM and NQO1 by PEIPC and PAPCOOH. This demonstrates the critical 
role of electrophilicity of these species in the activation of Nrf2.  Since electrophiles are 
known to attack nucleophilic cysteine residues in Keap1, it is likely that direct Keap1 
modification would be the mechanism for Nrf2 activation by oxidized phospholipids. This 
hypothesis is supported by a study where protein targets of oxidized PAPE were 
investigated. The authors reported that oxPAPE could directly bind to intracellular proteins 
(Gugiu et al., 2008). Even though Keap1 was not detected as one of the proteins that bind 
oxPAPE, probably because of the low detection limit of the assay, the study provides a 
proof of principle that oxidized phospholipids can directly bind to intracellular proteins.  
In addition to Keap1-Nrf2-ARE pathway, OA-NO2 also activated another cytoprotective 
pathway in human endothelial cells, the HSR. This was revealed for the first time by a 
genome-wide gene expression analysis where Nrf2-dependent and independent responses 
were analyzed in response to OA-NO2. The results showed that in addition to Nrf2-
dependent gene expression, OA-NO2 also activated several genes involved in HSR that are 
under the regulation of HSF1 and HSF2. In the data validation, transcription factor HSF1 
was identified to mediate the OA-NO2 induced expression of HSP70, but the detailed 
activation mechanism remains to be investigated. Activation of heat shock response is not 
fully understood, but it has been shown that the lipid peroxidation product 4-HNE can 
activate HSR by disrupting the interaction of HSP70 and HSF1 leading to HSF1-dependent 
gene expression (Jacobs & Marnett 2007). Furthermore, 4-HNE can directly bind to C267 of 
heat shock protein HSP70 (Carbone et al., 2004). Whether cysteine modification of HSPs by 
electrophiles such as 4-HNE or OA-NO2 leads to activation of HSR-dependent expression 
remains to be investigated but may serve as a mechanism for activation (Figure 17).  
In a recent study, it has been suggested that heat shock might activate Nrf2 by 
interaction of HSP90 and Keap1. It was hypothesized that heat shock and antioxidants 
increase HSP90 and Keap1 interaction, dissociation of Cul3-Keap1-Nrf2 complex, and 
activation of Nrf2 (Niture & Jaiswal 2010). However, in this thesis, Nrf2 did not regulate 
HSF1-related genes in primary endothelial cells and these two pathways were identified as 
being two independent responses. In addition, the expression of Nrf2 target gene HO-1 was 
not elevated in heat shock, suggesting that Nrf2 activation by HSP90 Keap1 interaction may 
not apply to all cell types. 
Furthermore, the transcriptional analysis revealed that OA-NO2 might have broader 
effects in the vasculature. The gene expression data showed that ETB expression is 
upregulated by OA-NO2 in Nrf2-dependent manner. ETB is a endothelial specific receptor 
for ET-1 and mediates the vasodilatory effect of ET-1 in the vasculature. ET-1 can also act as 
a vasoconstrictor via the ETA receptor, which is present in vascular smooth muscle cells. The 
vasodilatory effect mediated by the ETB receptor is thought to be a result in an increase in 
the amount of NO in the vessel wall (Schneider, Boesen, & Pollock 2007). Interestingly, OA-
NO2 treatment has been shown to increase the amount and phosphorylation of ·NO 
synthesizing enzyme eNOS in endothelial cells and in mice (Khoo et al., 2010). In addition, 
ETB receptor activation in response to ET-1 increases ·NO formation via the PI3K-Akt-
pathway (Liu et al., 2003). Therefore, OA-NO2 might modulate blood pressure via Nrf2-
dependent increase in ETB receptor expression, which would lead to increase in ·NO 
production and subsequent vasodilatation. 
6.2 DETECTION OF PROTEIN ADDUCTION 
Low and moderate concentrations of electrophiles can induce signaling actions but high 
concentrations are often considered toxic (Liebler 2008). Therefore, one of the challenges in 
studying endogenous electrophilic compounds is to be able to perform the reliable 
detection of free or adducted electrophiles from samples.  
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The first method for global discovery of protein targets of electrophiles was developed in 
the late 1990s when proteomics methods were introduced (Qiu, Benet, & Burlingame 1998). 
In this method, proteins are adducted with a radiolabel, run into a 2D SDS-PAGE after 
which autography is used to identify the location of the adducted proteins. These spots are 
excited and analyzed with MS-based techniques. The limitation of this method is the 
detection of more abundant protein targets including cytoskeletal proteins, chaperones, and 
enzymes of intermediary metabolism of the electrophiles. However, despite the limitations, 
the application of 2D gel-based proteomics together with radiolabeling provided the first 
method for global discovery of the protein targets of electrophiles. In addition to radiolabel, 
biotin-tagged electrophiles such as IAB and 1-biotinamido-4-(4'-
[maleimidoethylcyclohexane]-carboxamido)butane (BMCC) are used as probes to treat 
either proteins or peptides isolated from desired origin. After avidin capture of the biotin 
electrophile-protein adducts, MS based methods can be used to identify these adducted 
proteins (Liebler 2008). Using the biotin-avidin approach it has been demostrated that 
electrophiles have unique protein targets as only a 20% overlap was found in the protein 
sequences adducted with either BMCC or IAB (Shin et al., 2007). However, adding a biotin 
or other affinity or reporter molecule or label to electrophiles may alter their function. In 
order to avoid this problem, a click chemistry strategy was developed. In this technique, an 
azido group is introduced to the electrophile and an alkyne group to reporter molecule or 
affinity capture reagent. In a copper catalyzed reaction, a covalent linkage between azide 
and alkyne occurs allowing the capture of the electrophile-protein adducts. With click 
chemistry, multiple HSPs were detected as proteins for 4-HNE adduction (Vila et al., 2008). 
In this thesis, a recently developed technique utilizing β-ME exchange (Schopfer et al., 
2009) was used to study the binding of OA-NO2 and Keap1. In this method, an exchange 
reaction between an excess of added β-ME and electrophile-adducted protein coupled with 
HPLC-MS/MS is used to detect adducted electrophiles from plasma, organelles, cells and 
tissue homogenates. The method requires the use of internal standards for electrophiles but 
allows the quantification of adducted electrophiles. Here this method was used to identify 
the adduction of an individual protein, Keap1, and an electrophile, OA-NO2, but it can be 
utilized for the detection and quantification of endogenous concentrations of electrophiles 
(Rudolph et al., 2010b), and for studying the metabolism of an electrophile after its 
formation or administration (Rudolph et al., 2009). 
6.3 KEAP1 MODIFICATIONS BY ELECTROPHILES 
In the Keap1-Nrf2-ARE pathway, Keap1 functions as a sensor protein and detects increased 
levels of ROS, electrophiles and heavy metals leading to induction of Nrf2-dependent 
cytoprotective enzymes. Initially it was thought that the actin bound cytoplasmic protein 
Keap1 simply sequesters Nrf2 in the cytoplasm. Upon stimulus, the conformational change 
in Keap1 would liberate Nrf2 to be translocated to the nucleus (Dinkova-Kostova et al., 
2002). Now it is known that inducers are unable to dissociate Keap1-Nrf2 binding (Eggler et 
al., 2005) and that in basal conditions, Keap1 functions as an adaptor protein in the Cul3-
based E3 ligase complex resulting in rapid ubiquitination and subsequent degradation of 
Nrf2 (Cullinan et al., 2004; Kobayashi et al., 2004; Zhang et al., 2004). However, the key 
question is still how exactly Keap1 recognizes stress?   
Several laboratories have identified the specific cysteine residues in Keap1 which are 
modified by electrophiles using mass MS methods. The most frequently identified cysteine 
residues include C151, C257, C273, C288, C297, and C613 (Dinkova-Kostova et al., 2002; 
Eggler et al., 2005; Hong et al., 2005; Hong, Freeman, & Liebler 2005; Hu et al., 2011; 
Kobayashi et al., 2009; Luo et al., 2007). However, the results from MS studies are diverse 
and not always consistent, but it is clear that there is no single cysteine in Keap1 
responsible for electrophile adduction. When interpreting these results, it has to be taken 
into account that MS-based proteomic analysis usually lack the physiological surrounding 
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of a cell, let alone the whole body, leading to the fact that with high enough concentration 
of an electrophile all of the 27 cysteines in Keap1 can be modified. Since measuring 
endogenous electrophiles and protein-electrophile adduction in vivo has a major challenge, 
the degree and relevance of in vivo modification of individual Keap1 cysteines is difficult to 
interpret. However, it is clear that different electrophiles modify unique patterns of Keap1 
cysteines.    
While results from MS-based proteomic methods may be diverse, only three of the 27 
Keap1 cysteines are identified as being functionally important for the Keap1-Nrf2-ARE 
pathway. The functional importance of Keap1 C151, C273, and C288 is revealed mostly 
using luciferase reporter assays, but also confirmed in vivo in a transgenic complementation 
rescue mouse model (Yamamoto et al., 2008). Keap1 C273 and C288 are required in order 
that Keap1 can repress Nrf2 in basal conditions and C151 is important after induction of 
several electrophiles such as SFN (Zhang et al., 2004). However, it is known that Nrf2 can 
be activated also independent of Keap1 C151 in response to prostaglandins and the heavy 
metal arsenite (Kobayashi et al., 2009; Wang et al., 2008).  
In this thesis, OA-NO2 modified Keap1 cysteine residues C38, C226, C273, C288, and 
C489 assessed by MS. Two of these cysteines, C273 and C288, were found to be functionally 
important, because mutation of these residues resulted in the inability of Keap1 to repress 
ARE activation in basal conditions assessed by luciferase reporter assay. Keap1 C151 was 
not among the most reactive cysteines modified by OA-NO2. Nevertheless, it was included 
in the reporter assay experiment, because the critical role of C151 for Nrf2 activation has 
been demonstrated in multiple studies in response to several electrophiles such as SFN 
(Kobayashi et al., 2009; Yamamoto et al., 2008; Zhang & Hannink 2003). However, 
prostaglandins are thought to activate Nrf2 independent of Keap1 C151 (Kobayashi et al., 
2009). For this reason, both SFN and 15d-PGJ2 were used as controls. In line with the 
previously published data, ARE activation in response to SFN was totally abolished when 
Keap1 C151 was mutated to serine. In contrast, similar to 15d-PGJ2, OA-NO2 was found to 
activate ARE independent of Keap1 C151. Keap1 C151-independent activation of Nrf2 by 
OA-NO2 was also confirmed by others in a zebrafish model (Tsujita et al., 2011) (Figure 17). 
One of the proposed mechanisms for Nrf2 activation is the Keap1-Cul3 dissociation 
model. According to this model, Cul3-based E3 ligase complex rapidly degrades Nrf2 
under basal conditions. In response to electrophiles such as SFN, Keap1 C151 is modified 
and Keap1-Cul3 binding is disrupted. In this setting Nrf2 can escape the degradation 
system, translocate to nucleus and induce the expression of antioxidant genes (Zhang et al., 
2004). However, in this study it was found that OA-NO2 and 15d-PGJ2 do not cause the 
dissociation of Keap1 and Cul3 but rather increase their binding. SFN on the other hand 
decreased the binding as proposed in the Keap1-Cul3 dissociation model. These results 
demonstrated that OA-NO2 and 15d-PGJ2 share the same activation mechanism, which is 
independent of Keap1 C151, and does not involve Keap1-Cul3 dissociation. 
The results presented in this thesis also support the hypothesis that different 
electrophiles can modify specific cysteines in Keap1 and that each Nrf2 activating 
compound might have a unique cysteine code. This was first suggested by Kobayashi et al, 
who demonstrated that Keap1 C151 is the sensor for some electrophiles including SFN and 
tBHQ, but prostaglandins 15d-PGJ2 and PGA2 would be detected by C273 (Kobayashi et al., 
2009). In a subsequent study, they also demonstrated that OA-NO2 could modify Keap1 
C273 and would belong to the same group as 15d-PGJ2 and PGA2 (Tsujita et al., 2011). In 
addition to C273, the data presented did not deny the involvement of C288 as a sensor of 
prostaglandins or OA-NO2, and C288 was modified by 15d-PGJ2 assessed by MS 
(Kobayashi et al., 2009; Tsujita et al., 2011). In a more recent study, three separate sensors 
for endogenous signaling molecules were identified and C288 was demonstrated as the 
sensor for alkenals such as 4-HNE and acrolein. In this study, C273 was not recovered in 
the MS analysis and was therefore not examined (McMahon et al., 2010).  The results 
presented in this thesis demonstrate that OA-NO2 modifies both C273 and C288, the 
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functionally important Keap1 residues. Furthermore, C151 was not modified by OA-NO2 
nor it was needed for ARE activation suggesting that OA-NO2 might share the same Nrf2 
activation mechanism as prostaglandins, belonging to the group of activators that use 
Keap1 C273 and/or C288 but not C151 as a sensor (Figure 17).  
 
 
 
Figure 17. Hypothesis of mechanisms for action of OA-NO2 and PEIPC in vascular endothelial 
cells based on the results presented in this thesis. OA-NO2 activates two independent pathways, 
HSR and Keap1-Nrf2-ARE pathway. OA-NO2 induces the binding of HSFs to HSEs, and the 
induction of heat shock genes including DNAJA4, HSPB8, HSPA6, and HSPA1A. The HSPs 
encoded by these genes are known to increase cellular defence. OA-NO2 also modifies Keap1 
cysteines C38, C226, C257, C273, and C498, leading to the dissociation of Cul3 from Keap1 and 
nuclear translocation of Nrf2. From these cysteines, C273 and C288 were found functionally 
important. In the nucleus, Nrf2 binds to AREs and drives the expression of target genes such as 
HO-1, GCLM and NQO1, which encode cytoprotective enzymes. Furthermore, OA-NO2 increases 
the expression of the ETB receptor, which may participate to blood pressure regulation. PEIPC 
activates HO-1, GCLM and NQO1 in an Nrf2-dependent manner, although the detailed 
mechanism for activation remains to be investigated.  
6.4 THERAPEUTIC POTENTIAL OF ELECTROPHILES AND NRF2 
SIGNALING 
Endogenous fatty acid derived electrophiles are formed by oxidative and inflammatory 
events. For example, oxidized phospholipids such as the electrophilic PEIPC are detected 
from atherosclerotic lesions (Watson et al., 1997). In addition, increased levels of OA-NO2 
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can be detected from mitochondria during ischemia (Nadtochiy et al., 2009). At the same 
time, moderate concentrations of the administered electrophiles can be protective. For 
example, OA-NO2 may induce anti-inflammatory gene expression and inhibit 
inflammatory cell signaling (Cui et al., 2006), protect against myocardial I/R injury 
(Rudolph et al., 2010b), inhibit neointimal hyperplasia after injury (Cole et al., 2009), and 
reduce atherosclerosis (Rudolph et al., 2010a). As demonstrated in this thesis, Nrf2-
pathway might be one of the pathways that mediates the protective effects of OA-NO2. 
Activation of Nrf2 signaling is regarded as protective in the vasculature. While healthy 
endothelial cells produce Nrf2 regulated protective genes, cells in low shear stress areas, 
which are prone to the development of atherosclerotic lesions, have reduced expression of 
Nrf2-dependent and increased expression of inflammatory genes (Chen et al., 2003; 
Fledderus et al., 2008). In addition, in Nrf2 transduced aortas of balloon-denuded rabbits, 
reduced numbers of inflammation markers were detected (Levonen et al., 2007). However, 
in atherosclerotic apoE-/- mice, the lack of Nrf2 appears to be atheroprotective (Barajas et al., 
2011; Sussan et al., 2008). The reduced expression of scavenger receptor CD36 in apoE-/- 
Nrf2-/- mice might offer one explanation to this opposite effect. However, apoE-/- is a model 
of severe, advanced atherosclerosis, especially when high fat diet is included, and these 
data does not exclude the protective effect Nrf2 might have in the early events of 
atherosclerosis and therefore these findings need to be corroborated in other, more 
physiological, mouse models of atherosclerosis. In fact, preliminary data from our 
laboratory suggests that Nrf2 might protect against early atherosclerosis in LDLR knockout 
mice expressing ApoB100 only in normal diet (Ruotsalainen et al., unpublished) 
In addition to vascular disease, the role of Nrf2 in chemoprevention is extensively 
studied. Exogenous agents including SFN, oltipraz and benzo[a]pyrene (B[a]P) can active 
Nrf2-dependent enzymes that can eliminate carcinogens or their intermediates and thereby 
prevent DNA damage. Several in vivo studies using Nrf2-/- mice have verified the crucial 
role of Nrf2 in cancer protection. Nrf2-/- mice display increased sensitivity to chemical 
toxicants and carcinogens and are resistant to the protective action of chemoprotective 
compounds such as SFN, oltipraz and B[a]P. However, new data has revealed that while 
Nrf2 protects normal cells from transforming into cancer cells, it also promotes the survival 
of cancer cells. Genetic mutations of both Nrf2 and Keap1 in cancer cells are identified 
resulting in constitutive expression of Nrf2-dependent cytoprotective genes, which might 
be responsible for chemoresistance. However, there is no direct evidence for genotoxicity of 
exogenous agents, and no tumor promoting effects have been observed. It is possible that a 
genetic mutation results in more profound activation of cytoprotective genes compared to 
pharmacological activation, which may be sufficient to chemoprevention but not cancer 
promotion (Kwak & Kensler 2010). In the future, more experimental validation needs to be 
done to confirm or deny this interpretation.   
In a very recent study published in the New England Journal of Medicine, patients with 
advanced chronic kidney disease and type 2 diabetes received treatment with  bardoxolone 
methyl (also known as CDDO-Me), which significantly improved their kidney function as 
measured by glomerular filtration rate (Pergola et al., 2011). This is the first clinical study of 
this type. Bardoxolone methyl is an electrophile and a potent Nrf2 activator (Dinkova-
Kostova et al., 2005; Liby et al., 2005; Yates et al., 2007) and it has been postulated that the 
activation of Nrf2 via its interaction of Keap1 cysteines mediates the improvement of 
kidney function in chronic kidney disease patients (Pergola et al., 2011). Furthermore, only 
a mild and dose-related side-effects such as muscle spasms were observed in the 
bardoxolone methyl group indicating that both electrophiles and activation of Keap1-Nrf2-
ARE pathway may be promising therapeutic agents and have potential for use in disease 
prevention.  
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7 SUMMARY AND CONCLUSIONS 
The main findings of this thesis were: 
 
I  OxPAPC induced expression of cytoprotective enzymes in human primary 
endothelial cells and in murine arteries and the induction was mediated by the 
transcription factor Nrf2. PEIPC and PAPCOOH were identified as the Nrf2 
activating species in oxPAPC, and the electrophilic sn-2 side chain was found 
to be critical for the activation of Nrf2 target genes.  
 
II The genome-wide analysis of Nrf2-dependent and independent effects of OA-
NO2 on gene expression in human endothelial cells revealed that in addition to 
Nrf2-dependent gene expression, OA-NO2 also induced another cytoprotective 
pathway, the HSR. OA-NO2 activated heat shock genes that were under the 
regulation of HSF1. The two identified pathways acted independently of each 
other and may both serve as mediators of the cytoprotective effect that OA-
NO2 has in the vasculature. 
 
III The molecular mechanism through which OA-NO2 activated Nrf2 includes the 
modification of Keap1 cysteines C38, C226, C273, C288, and C489. Of these, 
C273 and C288 were revealed as functionally important cysteines, but the well-
known Keap1 sensor C151 was not modified by OA-NO2 nor was it needed for 
activation of Nrf2. In contrast to electrophiles such as SFN, but similar to 
prostaglandin 15d-PGJ2, OA-NO2 activates Nrf2 independent of Keap1 C151 
and does not dissociate Keap1 from Cul3.   
 
IV Nrf2 regulates the transcription of ETB in response to OA-NO2 in endothelial 
cells. Four putative ARE sequences were identified the promoter of the longest 
transcript of the ETB gene. 
 
Taken together, the results presented in this thesis demonstrate that endogenous 
molecules oxPAPC and OA-NO2 can act as signaling molecules and activate specific 
responses such as Nrf2 regulated signaling. In addition, this is the first study to show that 
OA-NO2 can induce genes involved in another cytoprotective pathway, HSR. The two 
identified pathways may mediate the beneficial effects of oxPAPC and OA-NO2 in the 
vasculature. Furthermore, both OA-NO2 and Nrf2 might have broader effects in the 
vasculature, as OA-NO2 may regulate blood pressure via Nrf2-dependent upregulation of 
ETB receptor. This study also reveals the molecular mechanism for Nrf2 activation by OA-
NO2, which involves a direct modification of Keap1 cysteine residues. The results presented 
in this thesis strengthen the view that different electrophiles activate the Nrf2 pathway by 
distinct cysteine modifications of Keap1. The data suggests that OA-NO2 may share the 
activation mechanism with cyclopentanone prostaglandins, using C273 or/and C288 in 
Keap1 as a sensor for Nrf2 activation. In the future, both electrophiles and activation of 
Nrf2 signaling pathway may be promising therapeutic agents and have potential uses in 
disease prevention. 
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Dysfunction of the vascular 
endothelium can lead to diseases 
such as atherosclerosis. In this 
thesis, the signaling potential 
of endogenous lipid oxidation 
and nitration products in the 
endothelium was investigated. 
The results demonstrate that 
electrophilic lipid oxidation and 
nitration products participate to 
cytoprotection via Nrf2 and HSF1 
transcription factors and may 
protect against early events of 
vascular diseases. 
 
